Patent Application
20230019280
Hepatitis B is one of the world's most prevalent diseases. Although most individuals resolve the infection following acute symptoms, approximately 30% of cases become chronic. 350-400 million people worldwide are estimated to have chronic hepatitis B, leading to 0.5-1 million deaths per year, due largely to the development of hepatocellular carcinoma, cirrhosis, and/or other complications. Hepatitis B is caused by hepatitis B virus (HBV), a noncytopathic, liver tropic DNA virus belonging to Hepadnaviridae family.
A limited number of drugs are currently approved for the management of chronic hepatitis B, including two formulations of alpha-interferon (standard and pegylated) and five nucleoside/nucleotide analogues (lamivudine, adefovir, entecavir, telbivudine, and tenofovir) that inhibit HBV DNA polymerase. At present, the first-line treatment choices are entecavir, tenofovir, or peg-interferon alfa-2a. However, peg-interferon alfa-2a achieves desirable serological milestones in only one third of treated patients, and is frequently associated with severe side effects. Entecavir and tenofovir require long-term or possibly lifetime administration to continuously suppress HBV replication, and may eventually fail due to emergence of drug-resistant viruses.
HBV is an enveloped virus with an unusual mode of replication, centering on the establishment of a covalently closed circular DNA (cccDNA) copy of its genome in the host cell nucleus. Pregenomic (pg) RNA is the template for reverse transcriptional replication of HBV DNA. The encapsidation of pg RNA, together with viral DNA polymerase, into a nucleocapsid is essential for the subsequent viral DNA synthesis.
Aside from being a critical structural component of the virion, the HBV envelope is a major factor in the disease process. In chronically infected individuals, serum levels of HBV surface antigen (HBsAg) can be as high as 400 μg/ml, driven by the propensity for infected cells to secrete non-infectious subviral particles at levels far in excess of infectious (Dane) particles. HBsAg comprises the principal antigenic determinant in HBV infection and is composed of the small, middle and large surface antigens (S, M and L, respectively). These proteins are produced from a single open reading frame as three separate N-glycosylated polypeptides through utilization of alternative transcriptional start sites (for L and MIS mRNAs) and initiation codons (for L, M, and S).
Although the viral polymerase and HBsAg perform distinct functions, both are essential proteins for the virus to complete its life cycle and be infectious. HBV lacking HBsAg is completely defective, and cannot infect or cause infection. HBsAg protects the virus nucleocapsid, begins the infectious cycle, and mediates morphogenesis and secretion of newly forming virus from the infected cell.
People chronically infected with HBV are usually characterized by readily detectable levels of circulating antibody specific to the viral capsid (HBc), with little, if any detectable levels of antibody to HBsAg. There is evidence that chronic carriers produce antibodies to HBsAg, but these antibodies are complexed with the circulating HBsAg, which can be present in mg/mL amounts in a chronic carrier's circulation. Reducing the amount of circulating levels of HBsAg might allow any present anti-HBsA to manage the infection. Further, even if nucleocapsids free of HBsAg were to be expressed or secreted into circulation (perhaps as a result of cell death), the high levels of anti-HBc would quickly complex with them and result in their clearance.
Studies have shown that the presence of subviral particles in a culture of infected hepatocytes may have a transactivating function on viral genomic replication, and the circulating surface antigen suppresses virus-specific immune response. Furthermore, the scarcity of virus-specific cytotoxic T lymphocytes (CTLs), that is a hallmark of chronic HBV infection, may be due to repression of MHC I presentation by intracellular expression of L and M in infected hepatocytes. Existing FDA-approved therapies do not significantly affect HBsAg serum levels.
Hepatitis D virus (HDV) is a small circular enveloped RNA virus that can propagate only in the presence of HBV. In particular, HDV requires the HBV surface antigen protein to propagate itself. Infection with both HBV and HDV results in more severe complications compared to infection with HBV alone. These complications include a greater likelihood of experiencing liver failure in acute infections and a rapid progression to liver cirrhosis, with an increased chance of developing liver cancer in chronic infections. In combination with hepatitis B virus, hepatitis D has the highest mortality rate of all the hepatitis infections. The routes of transmission of HDV are similar to those for HBV. Infection is largely restricted to persons at high risk of HBV infection, particularly injecting drug users and persons receiving clotting factor concentrates.
Currently, there is no effective antiviral therapy available for the treatment of acute or chronic type D hepatitis. Interferon-alfa, given weekly for 12 to 18 months, is the only licensed treatment for hepatitis D. Response to this therapy is limited-in only about one-quarter of patients is serum HDV RNA undetectable 6 months post therapy.
There is thus a need in the art for novel compounds and/or compositions that can be used to treat and/or prevent HBV and/or HBV-HDV infection in a subject. In certain embodiments, the compounds can be used in patients that are HBV and/or HBV-HDV infected, patients who are at risk of becoming HBV and/or HBV-HDV infected, and/or patients that are infected with drug-resistant HBV and/or HDV. The present invention addresses this need.
The present disclosure provides a compound of formula (I), or a salt, solvate, geometric isomer, stereoisomer, tautomer, and any mixtures thereof:
wherein the variables in (I) are defined elsewhere herein.
The present disclosure further provides a pharmaceutical composition comprising at least one compound of the disclosure and a pharmaceutically acceptable carrier.
The present disclosure further provides a method of treating, ameliorating, and/or preventing hepatitis virus infection in a subject. In certain embodiments, the method comprises administering to the subject a therapeutically effective amount of at least one compound of the disclosure. In certain embodiments, the method comprises administering to the subject a therapeutically effective amount of at least one composition of the disclosure.
The present disclosure further provides a method of reducing, reversing the increase, and/or minimizing levels of at least one selected from the group consisting of hepatitis B virus surface antigen (HBsAg), hepatitis B e-antigen (HBeAg), hepatitis B core protein, and pregenomic (pg) RNA, in a HBV-infected subject. In certain embodiments, the method comprises administering to the subject a therapeutically effective amount of at least one compound of the disclosure. In certain embodiments, the method comprises administering to the subject a therapeutically effective amount of at least one composition of the disclosure.
The disclosure relates, in certain aspects, to the discovery of certain substituted polyaromatic compounds that are useful to treat and/or prevent HBV and/or HBV-HDV infection and related conditions in a subject. In certain embodiments, the compounds inhibit and/or reduce HBsAg secretion in an HBV-infected and/or HBV-HDV-infected subject. In other embodiments, the compounds reduce or minimize levels of HBsAg in an HBV-infected and/or HBV-HDV-infected subject. In yet other embodiments, the compounds reduce or minimize levels of HBeAg in an HBV-infected and/or HBV-HDV-infected subject. In yet other embodiments, the compounds reduce or minimize levels of hepatitis B core protein in an HBV-infected and/or HBV-HDV-infected subject. In yet other embodiments, the compounds reduce or minimize levels of pg RNA in an HBV-infected and/or HBV-HDV-infected subject.
As used herein, each of the following terms has the meaning associated with it in this section.
Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Generally, the nomenclature used herein and the laboratory procedures in animal pharmacology, pharmaceutical science, separation science, and organic chemistry are those well-known and commonly employed in the art. It should be understood that the order of steps or order for performing certain actions is immaterial, so long as the present teachings remain operable. Moreover, two or more steps or actions can be conducted simultaneously or not.
The following non-limiting abbreviations are used herein: cccDNA, covalently closed circular DNA; CH2Cl2, methylene chloride; DMF, dimethylformamide; DMAP, 4-dimethylamino-pyridine; EtOAc, ethyl acetate; HBc, hepatitis B capsid; HBV, hepatitis B virus; HDV, hepatitis D virus; HBeAg, hepatitis B e-antigen; HBsAg, hepatitis B virus surface antigen; HPLC, high-performance liquid chromatography; IPA, isopropyl alcohol; MeOH, methanol; NaHCO3, sodium bicarbonate; pg RNA, pregenomic RNA; SiO2, silica; SPhos, 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl; THF, tetrahydrofuran.
As used herein, the articles “a” and “an” refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.
As used herein, the term “alkenyl,” employed alone or in combination with other terms, means, unless otherwise stated, a stable monounsaturated or diunsaturated straight chain or branched chain hydrocarbon group having the stated number of carbon atoms. Examples include vinyl, propenyl (or allyl), crotyl, isopentenyl, butadienyl, 1,3-pentadienyl, 1,4-pentadienyl, and the higher homologs and isomers. A functional group representing an alkene is exemplified by —CH2—CH═CH2.
As used herein, the term “alkoxy” employed alone or in combination with other terms means, unless otherwise stated, an alkyl group having the designated number of carbon atoms, as defined elsewhere herein, connected to the rest of the molecule via an oxygen atom, such as, for example, methoxy, ethoxy, 1-propoxy, 2-propoxy (or isopropoxy), and the higher homologs and isomers. A specific example is (C1-C3)alkoxy, such as, but not limited to, ethoxy and methoxy.
As used herein, the term “alkyl” by itself or as part of another substituent means, unless otherwise stated, a straight or branched chain hydrocarbon having the number of carbon atoms designated (i.e., C1-C10 means one to ten carbon atoms) and includes straight, branched chain, or cyclic substituent groups. Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, hexyl, and cyclopropylmethyl. A specific embodiment is (C1-C6)alkyl, such as, but not limited to, ethyl, methyl, isopropyl, isobutyl, n-pentyl, n-hexyl, and cyclopropylmethyl.
As used herein, the term “alkynyl” employed alone or in combination with other terms means, unless otherwise stated, a stable straight chain or branched chain hydrocarbon group with a triple carbon-carbon bond, having the stated number of carbon atoms. Non-limiting examples include ethynyl and propynyl, and the higher homologs and isomers. The term “propargylic” refers to a group exemplified by —CH2—C≡CH. The term “homopropargylic” refers to a group exemplified by —CH2CH2—C≡CH.
As used herein, the term “aromatic” refers to a carbocycle or heterocycle with one or more polyunsaturated rings and having aromatic character, i.e., having (4n+2) delocalized R (pi) electrons, where ‘n’ is an integer.
As used herein, the term “aryl” employed alone or in combination with other terms means, unless otherwise stated, a carbocyclic aromatic system containing one or more rings (typically one, two or three rings) wherein such rings may be attached together in a pendent manner, such as a biphenyl, or may be fused, such as naphthalene. Examples include phenyl, anthracyl, and naphthyl. Aryl groups also include, for example, phenyl or naphthyl rings fused with one or more saturated or partially saturated carbon rings (e.g., bicyclo[4.2.0]octa-1,3,5-trienyl, or indanyl), which can be substituted at one or more carbon atoms of the aromatic and/or saturated or partially saturated rings.
As used herein, the term “aryl-(C1-C6)alkyl” refers to a functional group wherein a one to six carbon alkanediyl chain is attached to an aryl group, e.g., —CH2CH2-phenyl or —CH2-phenyl (or benzyl). Specific examples are aryl-CH2— and aryl-CH(CH3)—. The term “substituted aryl-(C1-C6)alkyl” refers to an aryl-(C1-C6)alkyl functional group in which the aryl group is substituted. A specific example is [substituted aryl]-(CH2)—. Similarly, the term “heteroaryl-(C1-C6)alkyl” refers to a functional group wherein a one to three carbon alkanediyl chain is attached to a heteroaryl group, e.g., —CH2CH2-pyridyl. A specific example is heteroaryl-(CH2)—. The term “substituted heteroaryl-(C1-C6)alkyl” refers to a heteroaryl-(C1-C6)alkyl functional group in which the heteroaryl group is substituted. A specific example is [substituted heteroaryl]-(CH2)—.
In one aspect, the terms “co-administered” and “co-administration” as relating to a subject refer to administering to the subject a compound and/or composition of the disclosure along with a compound and/or composition that may also treat or prevent a disease or disorder contemplated herein. In certain embodiments, the co-administered compounds and/or compositions are administered separately, or in any kind of combination as part of a single therapeutic approach. The co-administered compound and/or composition may be formulated in any kind of combinations as mixtures of solids and liquids under a variety of solid, gel, and liquid formulations, and as a solution.
As used herein, the term “cycloalkyl” by itself or as part of another substituent refers to, unless otherwise stated, a cyclic chain hydrocarbon having the number of carbon atoms designated (i.e., C3-C6 refers to a cyclic group comprising a ring group consisting of three to six carbon atoms) and includes straight, branched chain, or cyclic substituent groups. Examples of (C3-C6)cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Cycloalkyl rings can be optionally substituted. Non-limiting examples of cycloalkyl groups include: cyclopropyl, 2-methyl-cyclopropyl, cyclopropenyl, cyclobutyl, 2,3-dihydroxycyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctanyl, decalinyl, 2,5-dimethylcyclopentyl, 3,5-dichlorocyclohexyl, 4-hydroxycyclohexyl, 3,3,5-trimethylcyclohex-1-yl, octahydropentalenyl, octahydro-1H-indenyl, 3a,4,5,6,7,7a-hexahydro-3H-inden-4-yl, decahydroazulenyl; bicyclo[6.2.0]decanyl, decahydronaphthalenyl, and dodecahydro-1H-fluorenyl. The term “cycloalkyl” also includes bicyclic hydrocarbon rings, non-limiting examples of which include bicyclo-[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, 1,3-dimethyl[2.2.1] heptan-2-yl, bicyclo[2.2.2]octanyl, and bicyclo[3.3.3]undecanyl.
As used herein, a “disease” is a state of health of a subject wherein the subject cannot maintain homeostasis, and wherein if the disease is not ameliorated then the subject's health continues to deteriorate.
As used herein, a “disorder” in a subject is a state of health in which the subject is able to maintain homeostasis, but in which the subject's state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the subject's state of health.
As used herein, the term “halide” refers to a halogen atom bearing a negative charge. The halide anions are fluoride (F−), chloride (Cl−), bromide (Br−), and iodide (I−).
As used herein, the term “halo” or “halogen” alone or as part of another substituent refers to, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
As used herein, the term “heteroalkenyl” by itself or in combination with another term refers to, unless otherwise stated, a stable straight or branched chain monounsaturated or diunsaturated hydrocarbon group consisting of the stated number of carbon atoms and one or two heteroatoms selected from the group consisting of O, N, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. Up to two heteroatoms may be placed consecutively. Examples include —CH═CH—O—CH3, —CH═CH—CH2—OH, —CH2—CH═N—OCH3, —CH═CH—N(CH3)—CH3, and —CH2—CH═CH—CH2—SH.
As used herein, the term “heteroalkyl” by itself or in combination with another term refers to, unless otherwise stated, a stable straight or branched chain alkyl group consisting of the stated number of carbon atoms and one or two heteroatoms selected from the group consisting of O, N, and S, and wherein the nitrogen and sulfur atoms may be optionally oxidized and the nitrogen heteroatom may be optionally quaternized. The heteroatom(s) may be placed at any position of the heteroalkyl group, including between the rest of the heteroalkyl group and the fragment to which it is attached, as well as attached to the most distal carbon atom in the heteroalkyl group. Examples include: —OCH2CH2CH3, —CH2CH2CH2OH, —CH2CH2NHCH3, —CH2SCH2CH3, and —CH2CH2S(═O)CH3. Up to two heteroatoms may be consecutive, such as, for example, —CH2NH—OCH3, or —CH2CH2SSCH3.
As used herein, the term “heteroaryl” or “heteroaromatic” refers to a heterocycle having aromatic character. A polycyclic heteroaryl may include one or more rings that are partially saturated. Examples include tetrahydroquinoline and 2,3-dihydrobenzofuryl.
As used herein, the term “heterocycle” or “heterocyclyl” or “heterocyclic” by itself or as part of another substituent refers to, unless otherwise stated, an unsubstituted or substituted, stable, mono- or multi-cyclic heterocyclic ring system that comprises carbon atoms and at least one heteroatom selected from the group consisting of N, O, and S, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen atom may be optionally quaternized. The heterocyclic system may be attached, unless otherwise stated, at any heteroatom or carbon atom that affords a stable structure. A heterocycle may be aromatic or non-aromatic in nature. In certain embodiments, the heterocycle is a heteroaryl.
Examples of non-aromatic heterocycles include monocyclic groups such as aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline, imidazoline, pyrazolidine, dioxolane, sulfolane, 2,3-dihydrofuran, 2,5-dihydrofuran, tetrahydrofuran, thiophane, piperidine, 1,2,3,6-tetrahydropyridine, 1,4-dihydropyridine, piperazine, morpholine, thiomorpholine, pyran, 2,3-dihydropyran, tetrahydropyran, 1,4-dioxane, 1,3-dioxane, homopiperazine, homopiperidine, 1,3-dioxepane, 4,7-dihydro-1,3-dioxepin and hexamethyleneoxide.
Examples of heteroaryl groups include pyridyl, pyrazinyl, pyrimidinyl (such as, but not limited to, 2- and 4-pyrimidinyl), pyridazinyl, thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,3,4-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,3,4-thiadiazolyl and 1,3,4-oxadiazolyl.
Examples of polycyclic heterocycles include indolyl (such as, but not limited to, 3-, 4-5-, 6- and 7-indolyl), indolinyl, quinolyl, tetrahydroquinolyl, isoquinolyl (such as, but not limited to, 1- and 5-isoquinolyl), 1,2,3,4-tetrahydroisoquinolyl, cinnolinyl, quinoxalinyl (such as, but not limited to, 2- and 5-quinoxalinyl), quinazolinyl, phthalazinyl, 1,8-naphthyridinyl, 1,4-benzodioxanyl, coumarin, dihydrocoumarin, 1,5-naphthyridinyl, benzofuryl (such as, but not limited to, 3-, 4-, 5-, 6- and 7-benzofuryl), 2,3-dihydrobenzofuryl, 1,2-benzisoxazolyl, benzothienyl (such as, but not limited to, 3-, 4-, 5-, 6-, and 7-benzothienyl), benzoxazolyl, benzothiazolyl (such as, but not limited to, 2-benzothiazolyl and 5-benzothiazolyl), purinyl, benzimidazolyl, benztriazolyl, thioxanthinyl, carbazolyl, carbolinyl, acridinyl, pyrrolizidinyl, and quinolizidinyl.
The aforementioned listing of heterocyclyl and heteroaryl moieties is intended to be representative and not limiting.
As used herein, the term “pharmaceutical composition” or “composition” refers to a mixture of at least one compound useful within the disclosure with a pharmaceutically acceptable carrier. The pharmaceutical composition facilitates administration of the compound to a subject.
As used herein, the term “pharmaceutically acceptable” refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound useful within the disclosure, and is relatively non-toxic, i.e., the material may be administered to a subject without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
As used herein, the term “pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the disclosure within or to the subject such that it may perform its intended function. Typically, such constructs are carried or transported from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, including the compound useful within the disclosure, and not injurious to the subject. Some examples of materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations. As used herein, “pharmaceutically acceptable carrier” also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible with the activity of the compound useful within the disclosure, and are physiologically acceptable to the subject. Supplementary active compounds may also be incorporated into the compositions. The “pharmaceutically acceptable carrier” may further include a pharmaceutically acceptable salt of the compound useful within the disclosure.
Other additional ingredients that may be included in the pharmaceutical compositions used in the practice of the disclosure are known in the art and described, for example in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, Pa.), which is incorporated herein by reference.
As used herein, the language “pharmaceutically acceptable salt” refers to a salt of the administered compound prepared from pharmaceutically acceptable non-toxic acids and/or bases, including inorganic acids, inorganic bases, organic acids, inorganic bases, solvates (including hydrates), and clathrates thereof.
As used herein, a “pharmaceutically effective amount,” “therapeutically effective amount,” or “effective amount” of a compound is that amount of compound that is sufficient to provide a beneficial effect to the subject to which the compound is administered.
The term “prevent,” “preventing,” or “prevention” as used herein means avoiding or delaying the onset of symptoms associated with a disease or condition in a subject that has not developed such symptoms at the time the administering of an agent or compound commences. Disease, condition and disorder are used interchangeably herein.
By the term “specifically bind” or “specifically binds” as used herein is meant that a first molecule preferentially binds to a second molecule (e.g., a particular receptor or enzyme), but does not necessarily bind only to that second molecule.
As used herein, the terms “subject” and “individual” and “patient” can be used interchangeably, and may refer to a human or non-human mammal or a bird. Non-human mammals include, for example, livestock and pets, such as ovine, bovine, porcine, canine, feline and murine mammals. In certain embodiments, the subject is human.
As used herein, the term “substituted” refers to that an atom or group of atoms has replaced hydrogen as the substituent attached to another group.
As used herein, the term “substituted alkyl,” “substituted cycloalkyl,” “substituted alkenyl” or “substituted alkynyl” refers to alkyl, cycloalkyl, alkenyl, or alkynyl, as defined elsewhere herein, substituted by one, two or three substituents independently selected from the group consisting of halogen, —OH, alkoxy, tetrahydro-2-H-pyranyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, 1-methyl-imidazol-2-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, —C(═O)OH, —C(═O)O(C1-C6)alkyl, trifluoromethyl, —C≡N, —C(═O)NH2, —C(═O)NH(C1-C6)alkyl, —C(═O)N((C1-C6)alkyl)2, —SO2NH2, —SO2NH(C1-C6 alkyl), —SO2N(C1-C6 alkyl)2, —C(═NH)NH2, and —NO2, in certain embodiments containing one or two substituents independently selected from halogen, —OH, alkoxy, —NH2, trifluoromethyl, —N(CH3)2, and —C(═O)OH, in certain embodiments independently selected from halogen, alkoxy, and —OH.
Examples of substituted alkyls include, but are not limited to, 2,2-difluoropropyl, 2-carboxycyclopentyl and 3-chloropropyl.
For aryl, aryl-(C1-C3)alkyl and heterocyclyl groups, the term “substituted” as applied to the rings of these groups refers to any level of substitution, namely mono-, di-, tri-, tetra-, or penta-substitution, where such substitution is permitted. The substituents are independently selected, and substitution may be at any chemically accessible position. In certain embodiments, the substituents vary in number between one and four. In other embodiments, the substituents vary in number between one and three. In yet another embodiments, the substituents vary in number between one and two. In yet other embodiments, the substituents are independently selected from the group consisting of C1-C6 alkyl, —OH, C1-C6 alkoxy, halogen, amino, acetamido, and nitro. As used herein, where a substituent is an alkyl or alkoxy group, the carbon chain may be branched, straight or cyclic.
Unless otherwise noted, when two substituents are taken together to form a ring having a specified number of ring atoms (e.g., two groups taken together with the nitrogen to which they are attached to form a ring having from 3 to 7 ring members), the ring can have carbon atoms and optionally one or more (e.g., 1 to 3) additional heteroatoms independently selected from nitrogen, oxygen, or sulfur. The ring can be saturated or partially saturated, and can be optionally substituted.
Whenever a term or either of their prefix roots appear in a name of a substituent the name is to be interpreted as including those limitations provided herein. For example, whenever the term “alkyl” or “aryl” or either of their prefix roots appear in a name of a substituent (e.g., arylalkyl, alkylamino) the name is to be interpreted as including those limitations given elsewhere herein for “alkyl” and “aryl” respectively.
In certain embodiments, substituents of compounds are disclosed in groups or in ranges. It is specifically intended that the description include each and every individual subcombination of the members of such groups and ranges. For example, the term “C1-6 alkyl” is specifically intended to individually disclose C1, C2, C3, C4, C5, C6, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2, C2-C6, C2-C5, C2-C4, C2-C3, C3-C6, C3-C5, C3-C4, C4-C6, C4-C5, and C5-C6 alkyl.
The terms “treat,” “treating” and “treatment,” as used herein, means reducing the frequency or severity with which symptoms of a disease or condition are experienced by a subject by virtue of administering an agent or compound to the subject.
Ranges: throughout this disclosure, various aspects of the disclosure can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosure. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual and partial numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.
The disclosure includes certain compound recited herein, as well as any salt, solvate, geometric isomer (such as, in a non-limiting example, any geometric isomer and any mixtures thereof, such as, in a non-limiting example, mixtures in any proportions of any geometric isomers thereof), stereoisomer (such as, in a non-limiting example, any enantiomer or diastereoisomer, and any mixtures thereof, such as, in a non-limiting example, mixtures in any proportions of any enantiomers and/or diastereoisomers thereof), tautomer (such as, in a non-limiting example, any tautomer and any mixtures thereof, such as, in a non-limiting example, mixtures in any proportions of any tautomers thereof), and any mixtures thereof.
The disclosure includes a compound of formula (I), or a salt, solvate, geometric isomer, stereoisomer, tautomer, and any mixtures thereof:
wherein in (I):
R1 is selected from the group consisting of:
X1 is a bond (absent) or CR2aR2b;
X2 is a bond (absent) or CR2CR2d;
each occurrence of X3 is independently selected from the group consisting of NR7a, O, and S;
each occurrence of X4 is independently selected from the group consisting of NR7b and CR5e;
each occurrence of Y1 is independently selected from the group consisting of N and CR6a; each occurrence of Y2 is independently selected from the group consisting of N and CR5a; each occurrence of R2a, R2b, R2c, R2d, R2e, and R2f is independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, halogen, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 hydroxyalkyl, —OR′, —(CH2)0-2C(═O)OR′, and —(CH2)0-2N(R′)(R′), wherein each occurrence of R′ is independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, and optionally substituted C3-C8 cycloalkyl;
each occurrence of R3a, R3b, R3c and R3d is independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, halogen, cyano, nitro, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 hydroxyalkyl, —OR′, —SR, —S(═O)R′, —S(O)2R′, and —N(R′)(R′), wherein each occurrence of R′ is independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, and optionally substituted C3-C8 cycloalkyl;
each occurrence of R4 is independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, and optionally substituted C3-C8 cycloalkyl;
each occurrence of R5a, R5b, R5c, R5d, and R5e is independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted phenyl, halogen, cyano, nitro, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 hydroxyalkyl, —OR′, —SR′, —S(═O)R′, —S(O)2R′, and —N(R′)(R′), wherein each occurrence of R′ is independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, and optionally substituted C3-C8 cycloalkyl;
each occurrence of R6a, R6b, R6c, and R6d is independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, halogen, cyano, nitro, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 hydroxyalkyl, —OR′, —SR′, —S(═O)R′, —S(O)2R′, and —N(R′)(R′), wherein each occurrence of R′ is independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, and optionally substituted C3-C8 cycloalkyl;
each occurrence of R7a and R7b is independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, and optionally substituted C3-C8 cycloalkyl;
each occurrence of R8 is independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, and optionally substituted C3-C8 cycloalkyl; and
each occurrence of R9 is independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, —S(═O)2 (optionally substituted C1-C6 alkyl), and —S(═O)2 (optionally substituted C3-C8 cycloalkyl).
In certain embodiments, the compound of formula (I) is:
In certain embodiments, the compound of formula (I) is:
In certain embodiments, the compound of formula (I) is:
In certain embodiments, the compound of formula (I) is:
In certain embodiments, the compound of formula (I) is:
In certain embodiments, each occurrence of R4 is independently selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
wherein Ph is optionally substituted. In yet other embodiments, R1 is
In certain embodiments, R1 is
In other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
wherein Ph is optionally substituted. In yet other embodiments, R1 is
In yet other embodiments, R1 is,
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
wherein R′″ is H, C1-C6 alkyl, or C3-C8 cycloalkyl. In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
wherein R′″ is H, C1-C6 alkyl, or C3-C8 cycloalkyl. In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In yet other embodiments, R1 is
In certain embodiments, X1 is a bond. In certain embodiments, X1 is CR2aR2b.
In certain embodiments, X2 is a bond. In certain embodiments, X2 is CR2cR2d.
In certain embodiments, X3 is NR7a. In certain embodiments, X3 is O. In certain embodiments, X3 is S.
In certain embodiments, X4 is NR7b. In certain embodiments, X4 is CR5e.
In certain embodiments, Y1 is N. In certain embodiments, Y is CR6a.
In certain embodiments, Y2 is N. In certain embodiments, Y is CR5a.
In certain embodiments, each occurrence of R2a, R2b, R2c, R2d, R2e, and R2f is independently selected from the group consisting of H, C1-C6 alkyl, phenyl, pyridinyl, and thiophenyl, each of which optionally substituted.
In certain embodiments, R2a and R2b, and/or R2c and R2d, and/or R2e and R2f independently combine with the carbon atom to which both of them are bound to form a substituent selected from the group consisting of 1,1-cyclopropanediyl, 1,1-cyclobutanediyl, 1,1-cyclopentanediyl, and 1,1-cyclohexanediyl.
In certain embodiments, each occurrence of R3a, R3b, R3c, and R3d is independently selected from the group consisting of H, halogen (such as, but not limited to F or Cl), C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C1-C6 haloalkoxy.
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, the
ring is
In certain embodiments, each occurrence of Ra is independently C1-C6 alkyl. In certain embodiments, each occurrence of Rb is independently C1-C6 alkyl. In certain embodiments, each occurrence of Ra is independently C1-C5 alkyl. In certain embodiments, each occurrence of Rb is independently C1-C5 alkyl. In certain embodiments, each occurrence of Ra is independently C1-C4 alkyl. In certain embodiments, each occurrence of Rb is independently C1-C4 alkyl.
In certain embodiments, each occurrence of Ra is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, or tert-butyl. In certain embodiments, each occurrence of Rb is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, or tert-butyl.
In certain embodiments, two of R5a, R5b, R5c, R5d, and R5e bound to adjacent carbon atoms combine to form optionally substituted 5-membered carbocyclyl or heterocyclyl. In certain embodiments, two of R5a, R5b, R5c, R5d, and R5e bound to adjacent carbon atoms combine to form optionally substituted 6-membered carbocyclyl or heterocyclyl. In certain embodiments, two of R5a, R5b, R5c, R5d, and R5e bound to adjacent carbon atoms combine to form optionally substituted 7-membered carbocyclyl or heterocyclyl.
In certain embodiments, two of R5a, R5b, R5c, R5d, and R5e bound to adjacent carbon atoms combine to form —S—CR′═N—, wherein R′ is H or C1-C6 alkyl. In certain embodiments, two of R5a, R5b, R5c, R5d, and R5e bound to adjacent carbon atoms combine to form —N═CR′—S—, wherein R′ is H or C1-C6 alkyl. In certain embodiments, two of R5a, R5b, R5c, R5d, and R5e bound to adjacent carbon atoms combine to form —(CH2)3—, wherein each methylene group is optionally substituted with one or two independently selected halogen or C1-C6 alkyl. In certain embodiments, two of R5a, R5b, R5c, R5d, and R5e bound to adjacent carbon atoms combine to form —CH2OCH2—, —OCH2CH2—, or —CH2CH2O—, wherein each methylene group is optionally substituted with one or two independently selected halogen or C1-C6 alkyl. In certain embodiments, two of R5a, R5b, R5c, R5d, and R5e bound to adjacent carbon atoms combine to form —OCH═CH— or —CH═CHO—, wherein each CH group is optionally substituted with one independently selected halogen or C1-C6 alkyl.
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, R1 is
In certain embodiments, each occurrence of alkyl, alkylenyl (alkylene), cycloalkyl, heterocyclyl, or carbocyclyl is independently optionally substituted with at least one substituent selected from the group consisting of C1-C6 alkyl, halogen, —OR″, phenyl (thus yielding, in non-limiting examples, optionally substituted phenyl-(C1-C3 alkyl), such as, but not limited to, benzyl or substituted benzyl), and —N(R″)(R″), wherein each occurrence of R″ is independently H, C1-C6 alkyl or C3-C8 cycloalkyl.
In certain embodiments, each occurrence of aryl or heteroaryl is independently optionally substituted with at least one substituent selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, halogen, —CN, —OR″, —N(R″)(R″), —NO2, —S(═O)2N(R″)(R″), acyl, and C1-C6 alkoxycarbonyl, wherein each occurrence of R″ is independently H, C1-C6 alkyl or C3-C8 cycloalkyl.
In certain embodiments, each occurrence of aryl or heteroaryl is independently optionally substituted with at least one substituent selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, halogen, —CN, —OR″, —N(R″)(R″), and C1-C6 alkoxycarbonyl, wherein each occurrence of R″ is independently H, C1-C6 alkyl or C3-C8 cycloalkyl.
In certain embodiments, the compounds of the disclosure, or a salt, solvate, stereoisomer (such as, in a non-limiting example, an enantiomer or diastereoisomer thereof), any mixture of one or more stereoisomers (such as, in a non-limiting example, mixtures in any proportion of enantiomers thereof, and/or mixtures in any proportion of diastereoisomers thereof), tautomer, and/or any mixture of tautomers thereof, are recited in Table 1.
In certain embodiments, the compound of the disclosure is:
In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is 2′-([2,2′-bipyrimidin]-4-yl)-5′,6′-dimethoxyspiro[cyclopropane-1,1′-isoindolin]-3′-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is 2′-([2,2′-bipyrimidin]-4-yl)-6′-fluoro-5′-methoxyspiro[cyclopropane-1,1′-isoindolin]-3′-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is 2-([2,2′-bipyrimidin]-4-yl)-5,7-difluoroisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is 2-([2,2′-bipyrimidin]-4-yl)-5,6-difluoroisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is 2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is 2-([2,2′-bipyrimidin]-4-yl)-6,7-dimethoxy-3,4-dihydroisoquinolin-1(2H)-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is 2-([2,2′-bipyrimidin]-4-yl)-5,7-difluoro-3,4-dihydroisoquinolin-1(2H)-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is 2-([2,2′-bipyrimidin]-4-yl)-6,7-dimethoxy-1,4-dihydroisoquinolin-3(2H)-one.
In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-4-yl)-3-ethyl-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-4-yl)-3-ethyl-5-methoxy-6-methylisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-4-yl)-6-chloro-3-ethyl-5-methoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-4-yl)-6-chloro-3-ethyl-4-fluoroisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(4-methoxyphenyl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(3-methoxyphenyl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-4-yl)-3-benzyl-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(3,3,3-trifluoropropyl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(6-methylpyridin-3-yl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-4-yl)-5-chloro-3-ethyl-7-fluoroisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(pyridin-2-yl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-(5,6-dimethyl-[2,2′-bipyrimidin]-4-yl)-3-ethyl-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-3-ethyl-5-fluoro-6-methoxy-2-(5-methoxy-[2,2′-bipyrimidin]-4-yl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-4-yl)-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(3-methylthiophen-2-yl)isoindo-lin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-4-yl)-3-cyclobutyl-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(tetrahydro-2H-pyran-4-yl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-3-ethyl-5,6-dimethoxy-2-(2-pyrimidin-2-ylpyrimidin-5-yl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-3-ethyl-5,6-dimethoxy-2-(6-(pyrimidin-2-yl)pyridin-2-yl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-3-ethyl-5,6-dimethoxy-2-(2-(pyrimidin-2-yl)pyridin-4-yl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-3-ethyl-5,6-dimethoxy-2-(6-(pyrimidin-2-yl)pyrazin-2-yl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-3-ethyl-5,6-dimethoxy-2-(6-methyl-[2,2′-bipyrimidin]-4-yl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,4′-bipyrimidin]-6′-yl)-3-ethyl-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-propylisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-4-yl)-3-isobutyl-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-phenylisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-4-yl)-3-(tert-butyl)-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-4-yl)-3-ethyl-5-fluoro-6-methoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-3-ethyl-5-fluoro-6-methoxy-2-(2-pyrimidin-2-ylpyrimidin-4-yl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-4-yl)-3-ethyl-6-fluoro-5-methoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-4-yl)-5-fluoro-6-methoxy-3-(2-methoxyethyl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-3-ethyl-5-fluoro-2-(5-fluoro-2-pyrimidin-2-yl-pyrimidin-4-yl)-6-methoxy-isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-6-ethoxy-3-ethyl-5-fluoro-2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-3-ethyl-5-fluoro-2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)-6-isopropoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-5-fluoro-2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)-6-methoxy-3-propylisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-([2,2′-bipyrimidin]-5-yl)-3-ethyl-5,6-difluoroisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-3-ethyl-2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-3-ethyl-2-(6-fluoro-[2,2′-bipyrimidin]-4-yl)-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-phenylisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-3-ethyl-2-(5′-fluoro-[2,2′-bipyrimidin]-4-yl)-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (R)-3-ethyl-5-fluoro-2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)-6-methoxyisoindolin-1-one.
In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-4-yl)-3-ethyl-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-4-yl)-3-ethyl-5-methoxy-6-methylisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-4-yl)-6-chloro-3-ethyl-5-methoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-4-yl)-6-chloro-3-ethyl-4-fluoroisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(4-methoxyphenyl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(3-methoxyphenyl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-4-yl)-3-benzyl-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(3,3,3-trifluoropropyl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(6-methylpyridin-3-yl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-4-yl)-5-chloro-3-ethyl-7-fluoroisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(pyridin-2-yl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-(5,6-dimethyl-[2,2′-bipyrimidin]-4-yl)-3-ethyl-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-3-ethyl-5-fluoro-6-methoxy-2-(5-methoxy-[2,2′-bipyrimidin]-4-yl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-4-yl)-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(3-methylthiophen-2-yl)isoindo-lin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-4-yl)-3-cyclobutyl-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(tetrahydro-2H-pyran-4-yl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-3-ethyl-5,6-dimethoxy-2-(2-pyrimidin-2-ylpyrimidin-5-yl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-3-ethyl-5,6-dimethoxy-2-(6-(pyrimidin-2-yl)pyridin-2-yl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-3-ethyl-5,6-dimethoxy-2-(2-(pyrimidin-2-yl)pyridin-4-yl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-3-ethyl-5,6-dimethoxy-2-(6-(pyrimidin-2-yl)pyrazin-2-yl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-3-ethyl-5,6-dimethoxy-2-(6-methyl-[2,2′-bipyrimidin]-4-yl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,4′-bipyrimidin]-6′-yl)-3-ethyl-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-propylisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-4-yl)-3-isobutyl-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-phenylisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-4-yl)-3-(tert-butyl)-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-4-yl)-3-ethyl-5-fluoro-6-methoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-3-ethyl-5-fluoro-6-methoxy-2-(2-pyrimidin-2-ylpyrimidin-4-yl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-4-yl)-3-ethyl-6-fluoro-5-methoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-4-yl)-5-fluoro-6-methoxy-3-(2-methoxyethyl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-3-ethyl-5-fluoro-2-(5-fluoro-2-pyrimidin-2-yl-pyrimidin-4-yl)-6-methoxy-isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-6-ethoxy-3-ethyl-5-fluoro-2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)isoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-3-ethyl-5-fluoro-2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)-6-isopropoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-5-fluoro-2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)-6-methoxy-3-propylisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-([2,2′-bipyrimidin]-5-yl)-3-ethyl-5,6-difluoroisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-3-ethyl-2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-3-ethyl-2-(6-fluoro-[2,2′-bipyrimidin]-4-yl)-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-phenylisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-3-ethyl-2-(5′-fluoro-[2,2′-bipyrimidin]-4-yl)-5,6-dimethoxyisoindolin-1-one. In certain embodiments, the compound, or a salt, solvate, or tautomer thereof, is (S)-3-ethyl-5-fluoro-2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)-6-methoxyisoindolin-1-one.
The compounds of the disclosure may possess one or more stereocenters, and each stereocenter may exist independently in either the (R) or (S) configuration. In certain embodiments, compounds described herein are present in optically active or racemic forms. The compounds described herein encompass racemic, optically active, regioisomeric and stereoisomeric forms, or combinations thereof that possess the therapeutically useful properties described herein. Preparation of optically active forms is achieved in any suitable manner, including by way of non-limiting example, by resolution of the racemic form with recrystallization techniques, synthesis from optically active starting materials, chiral synthesis, or chromatographic separation using a chiral stationary phase. A compound illustrated herein by the racemic formula further represents either of the two enantiomers or mixtures thereof, or in the case where two or more chiral center are present, all diastereomers or mixtures thereof.
In certain embodiments, the compounds of the disclosure exist as tautomers. All tautomers are included within the scope of the compounds recited herein.
Compounds described herein also include isotopically labeled compounds wherein one or more atoms is replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes suitable for inclusion in the compounds described herein include and are not limited to 2H, 3H, 11C, 13C, 14C, 36Cl, 18F, 123I, 125I, 13N, 15N, 15O, 17O, 18O, 32P, and 35S. In certain embodiments, substitution with heavier isotopes such as deuterium affords greater chemical stability. Isotopically labeled compounds are prepared by any suitable method or by processes using an appropriate isotopically labeled reagent in place of the non-labeled reagent otherwise employed.
In certain embodiments, the compounds described herein are labeled by other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.
In all of the embodiments provided herein, examples of suitable optional substituents are not intended to limit the scope of the claimed disclosure. The compounds of the disclosure may contain any of the substituents, or combinations of substituents, provided herein.
The compounds described herein may form salts with acids or bases, and such salts are included in the present disclosure. The term “salts” embraces addition salts of free acids or bases that are useful within the methods of the disclosure. The term “pharmaceutically acceptable salt” refers to salts that possess toxicity profiles within a range that affords utility in pharmaceutical applications. In certain embodiments, the salts are pharmaceutically acceptable salts. Pharmaceutically unacceptable salts may nonetheless possess properties such as high crystallinity, which have utility in the practice of the present disclosure, such as for example utility in process of synthesis, purification or formulation of compounds useful within the methods of the disclosure.
Suitable pharmaceutically acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid. Examples of inorganic acids include sulfate, hydrogen sulfate, hydrochloric, hydrobromic, hydriodic, nitric, carbonic, sulfuric, and phosphoric acids (including hydrogen phosphate and dihydrogen phosphate). Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which include formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (or pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, sulfanilic, 2-hydroxyethanesulfonic, trifluoromethanesulfonic, p-toluenesulfonic, cyclohexylaminosulfonic, stearic, alginic, (3-hydroxybutyric, salicylic, galactaric, galacturonic acid, glycerophosphonic acids and saccharin (e.g., saccharinate, saccharate). Salts may be comprised of a fraction of one, one or more than one molar equivalent of acid or base with respect to any compound of the disclosure.
Suitable pharmaceutically acceptable base addition salts of compounds of the disclosure include, for example, ammonium salts and metallic salts including alkali metal, alkaline earth metal and transition metal salts such as, for example, calcium, magnesium, potassium, sodium and zinc salts. Pharmaceutically acceptable base addition salts also include organic salts made from basic amines such as, for example, N,N′-dibenzylethylene-diamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (or N-methylglucamine) and procaine. All of these salts may be prepared from the corresponding compound by reacting, for example, the appropriate acid or base with the compound.
In one aspect, the compounds of the disclosure are useful within the methods of the disclosure in combination with one or more additional agents useful for treating HBV and/or HDV infections. These additional agents may comprise compounds or compositions identified herein, or compounds (e.g., commercially available compounds) known to treat, prevent, or reduce the symptoms of HBV and/or HDV infections.
Non-limiting examples of one or more additional agents useful for treating HBV and/or HDV infections include: (a) reverse transcriptase inhibitors; (b) capsid inhibitors; (c) cccDNA formation inhibitors; (d) RNA destabilizers; (e) oligomeric nucleotides targeted against the HBV genome; (f) immunostimulators, such as checkpoint inhibitors; and (g) GalNAc-siRNA conjugates targeted against an HBV gene transcript.
(a) Reverse Transcriptase Inhibitors
In certain embodiments, the reverse transcriptase inhibitor is a reverse-transcriptase inhibitor (NARTI or NRTI). In other embodiments, the reverse transcriptase inhibitor is a nucleotide analog reverse-transcriptase inhibitor (NtARTI or NtRTI).
Reported reverse transcriptase inhibitors include, but are not limited to, entecavir, clevudine, telbivudine, lamivudine, adefovir, and tenofovir, tenofovir disoproxil, tenofovir alafenamide, adefovir dipovoxil, (1R,2R,3R,5R)-3-(6-amino-9H-9-purinyl)-2-fluoro-5-(hydroxymethyl)-4-methylenecyclopentan-1-ol (described in U.S. Pat. No. 8,816,074, incorporated herein in its entirety by reference), emtricitabine, abacavir, elvucitabine, ganciclovir, lobucavir, famciclovir, penciclovir, and amdoxovir.
Reported reverse transcriptase inhibitors further include, but are not limited to, entecavir, lamivudine, and (1R,2R,3R,5R)-3-(6-amino-9H-9-purinyl)-2-fluoro-5-(hydroxymethyl)-4-methylenecyclopentan-1-ol.
Reported reverse transcriptase inhibitors further include, but are not limited to, a covalently bound phosphoramidate or phosphonamidate moiety of the above-mentioned reverse transcriptase inhibitors, or as described in for example U.S. Pat. No. 8,816,074, US Patent Application Publications No. US 2011/0245484 A1, and US 2008/0286230A1, all of which incorporated herein in their entireties by reference.
Reported reverse transcriptase inhibitors further include, but are not limited to, nucleotide analogs that comprise a phosphoramidate moiety, such as, for example, methyl ((((1R,3R,4R,5R)-3-(6-amino-9H-purin-9-yl)-4-fluoro-5-hydroxy-2-methylenecyclopentyl) methoxy)(phenoxy) phosphoryl)-(D or L)-alaninate and methyl ((((1R,2R,3R,4R)-3-fluoro-2-hydroxy-5-methylene-4-(6-oxo-1,6-dihydro-9H-purin-9-yl)cyclopentyl)methoxy)(phenoxy) phosphoryl)-(D or L)-alaninate. Also included are the individual diastereomers thereof, which include, for example, methyl ((R)-(((1R,3R,4R,5R)-3-(6-amino-9H-purin-9-yl)-4-fluoro-5-hydroxy-2-methylenecyclopentyl)methoxy)(phenoxy)phosphoryl)-(D or L)-alaninate and methyl ((S)-(((1R,3R,4R,5R)-3-(6-amino-9H-purin-9-yl)-4-fluoro-5-hydroxy-2-methylenecyclopentyl) methoxy)(phenoxy)phosphoryl)-(D or L)-alaninate.
Reported reverse transcriptase inhibitors further include, but are not limited to, compounds comprising a phosphonamidate moiety, such as, for example, tenofovir alafenamide, as well as those described in U.S. Patent Application Publication No. US 2008/0286230 A1, incorporated herein in its entirety by reference. Methods for preparing stereoselective phosphoramidate or phosphonamidate containing actives are described in, for example, U.S. Pat. No. 8,816,074, as well as U.S. Patent Application Publications No. US 2011/0245484 A1 and US 2008/0286230 A1, all of which incorporated herein in their entireties by reference.
(b) Capsid Inhibitors
As described herein, the term “capsid inhibitor” includes compounds that are capable of inhibiting the expression and/or function of a capsid protein either directly or indirectly. For example, a capsid inhibitor may include, but is not limited to, any compound that inhibits capsid assembly, induces formation of non-capsid polymers, promotes excess capsid assembly or misdirected capsid assembly, affects capsid stabilization, and/or inhibits encapsidation of RNA (pgRNA). Capsid inhibitors also include any compound that inhibits capsid function in a downstream event(s) within the replication process (e.g., viral DNA synthesis, transport of relaxed circular DNA (rcDNA) into the nucleus, covalently closed circular DNA (cccDNA) formation, virus maturation, budding and/or release, and the like). For example, in certain embodiments, the inhibitor detectably inhibits the expression level or biological activity of the capsid protein as measured, e.g., using an assay described herein. In certain embodiments, the inhibitor inhibits the level of rcDNA and downstream products of viral life cycle by at least 5%, at least 10%, at least 20%, at least 50%, at least 75%, or at least 90%.
Reported capsid inhibitors include, but are not limited to, compounds described in International Patent Applications Publication Nos WO 2013006394, WO 2014106019, and WO2014089296, all of which incorporated herein in their entireties by reference.
Reported capsid inhibitors also include, but are not limited to, the following compounds and pharmaceutically acceptable salts and/or solvates thereof: Bay-41-4109 (see Int'l Patent Application Publication No. WO 2013144129), AT-61 (see Int'l Patent Application Publication No. WO 1998033501; and King, et al., 1998, Antimicrob. Agents Chemother. 42(12):3179-3186), DVR-01 and DVR-23 (see Int'l Patent Application Publication No. WO 2013006394; and Campagna, et al., 2013, J. Virol. 87(12):6931, all of which incorporated herein in their entireties by reference.
In addition, reported capsid inhibitors include, but are not limited to, those generally and specifically described in U.S. Patent Application Publication Nos. US 2015/0225355, US 2015/0132258, US 2016/0083383, US 2016/0052921, US 2019/0225593, and Int'l Patent Application Publication Nos. WO 2013096744, WO 2014165128, WO 2014033170, WO 2014033167, WO 2014033176, WO 2014131847, WO 2014161888, WO 2014184350, WO 2014184365, WO 2015059212, WO 2015011281, WO 2015118057, WO 2015109130, WO 2015073774, WO 2015180631, WO 2015138895, WO 2016089990, WO 2017015451, WO 2016183266, WO 2017011552, WO 2017048950, WO2017048954, WO 2017048962, WO 2017064156, WO 2018052967, WO 2018172852, and are incorporated herein in their entirety by reference.
(c) cccDNA Formation Inhibitors
Covalently closed circular DNA (cccDNA) is generated in the cell nucleus from viral rcDNA and serves as the transcription template for viral mRNAs. As described herein, the term “cccDNA formation inhibitor” includes compounds that are capable of inhibiting the formation and/or stability of cccDNA either directly or indirectly. For example, a cccDNA formation inhibitor may include, but is not limited to, any compound that inhibits capsid disassembly, rcDNA entry into the nucleus, and/or the conversion of rcDNA into cccDNA. For example, in certain embodiments, the inhibitor detectably inhibits the formation and/or stability of the cccDNA as measured, e.g., using an assay described herein. In certain embodiments, the inhibitor inhibits the formation and/or stability of cccDNA by at least 5%, at least 10%, at least 20%, at least 50%, at least 75%, or at least 90%.
Reported cccDNA formation inhibitors include, but are not limited to, compounds described in Int'l Patent Application Publication No. WO 2013130703, and are incorporated herein in their entirety by reference.
In addition, reported cccDNA formation inhibitors include, but are not limited to, those generally and specifically described in U.S. Patent Application Publication No. US 2015/0038515 A1, and are incorporated herein in their entirety by reference.
(d) RNA Destabilizer
As used herein, the term “RNA destabilizer” refers to a molecule, or a salt or solvate thereof, that reduces the total amount of HBV RNA in mammalian cell culture or in a live human subject. In a non-limiting example, an RNA destabilizer reduces the amount of the RNA transcript(s) encoding one or more of the following HBV proteins: surface antigen, core protein, RNA polymerase, and e antigen. In certain embodiments, the RNA destabilizer reduces the total amount of HBV RNA in mammalian cell culture or in a live human subject by at least 5%, at least 10%, at least 20%, at least 50%, at least 75%, or at least 90%.
Reported RNA destabilizers include compounds described in U.S. Pat. No. 8,921,381, as well as compounds described in U.S. Patent Application Publication Nos. US 2015/0087659 and US 2013/0303552, all of which are incorporated herein in their entireties by reference.
In addition, reported RNA destabilizers include, but are not limited to, those generally and specifically described in Int'l Patent Application Publication Nos. WO 2015113990, WO 2015173164, US 2016/0122344, WO 2016107832, WO 2016023877, WO 2016128335, WO 2016177655, WO 2016071215, WO 2017013046, WO 2017016921, WO 2017016960, WO 2017017042, WO 2017017043, WO 2017102648, WO 2017108630, WO 2017114812, WO 2017140821, WO 2018085619, and are incorporated herein in their entirety by reference.
(e) Oligomeric Nucleotides Targeted Against the HBV Genome
Reported oligomeric nucleotides targeted against the HBV genome include, but are not limited to, Arrowhead-ARC-520 (see U.S. Pat. No. 8,809,293; and Wooddell et al., 2013, Molecular Therapy 21(5):973-985, all of which incorporated herein in their entireties by reference).
In certain embodiments, the oligomeric nucleotides can be designed to target one or more genes and/or transcripts of the HBV genome. Oligomeric nucleotide targeted to the HBV genome also include, but are not limited to, isolated, double stranded, siRNA molecules, that each include a sense strand and an antisense strand that is hybridized to the sense strand. In certain embodiments, the siRNA target one or more genes and/or transcripts of the HBV genome.
(f) Immunostimulators
Checkpoint Inhibitors
As described herein, the term “checkpoint inhibitor” includes any compound that is capable of inhibiting immune checkpoint molecules that are regulators of the immune system (e.g., stimulate or inhibit immune system activity). For example, some checkpoint inhibitors block inhibitory checkpoint molecules, thereby stimulating immune system function, such as stimulation of T cell activity against cancer cells. A non-limiting example of a checkpoint inhibitor is a PD-L1 inhibitor.
(g) GalNAc-siRNA Conjugates Targeted Against an HBV Gene Transcript
“GalNAc” is the abbreviation for N-acetylgalactosamine, and “siRNA” is the abbreviation for small interfering RNA. An siRNA that targets an HBV gene transcript is covalently bonded to GalNAc in a GalNAc-siRNA conjugate useful in the practice of the present disclosure. While not wishing to be bound by theory, it is believed that GalNAc binds to asialoglycoprotein receptors on hepatocytes thereby facilitating the targeting of the siRNA to the hepatocytes that are infected with HBV. The siRNA enter the infected hepatocytes and stimulate destruction of HBV gene transcripts by the phenomenon of RNA interference.
Examples of GalNAc-siRNA conjugates useful in the practice of this aspect of the present disclosure are set forth in published international application PCT/CA2017/050447 (PCT Application Publication number WO/2017/177326, published on Oct. 19, 2017) which is hereby incorporated by reference in its entirety.
A synergistic effect may be calculated, for example, using suitable methods such as, for example, the Sigmoid-Emax equation (Holford & Scheiner, 1981, Clin. Pharmacokinet. 6:429-453), the equation of Loewe additivity (Loewe & Muischnek, 1926, Arch. Exp. Pathol Pharmacol. 114: 313-326) and the median-effect equation (Chou & Talalay, 1984, Adv. Enzyme Regul. 22:27-55). Each equation referred to elsewhere herein may be applied to experimental data to generate a corresponding graph to aid in assessing the effects of the drug combination. The corresponding graphs associated with the equations referred to elsewhere herein are the concentration-effect curve, isobologram curve and combination index curve, respectively.
The present disclosure further provides methods of preparing the compounds of the present disclosure. Compounds of the present teachings can be prepared in accordance with the procedures outlined herein, from commercially available starting materials, compounds known in the literature, or readily prepared intermediates, by employing standard synthetic methods and procedures known to those skilled in the art. Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be readily obtained from the relevant scientific literature or from standard textbooks in the field. It should be contemplated that the disclosure includes each and every one of the synthetic schemes described and/or depicted herein.
It is appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, and so forth) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions can vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures. Those skilled in the art of organic synthesis will recognize that the nature and order of the synthetic steps presented can be varied for the purpose of optimizing the formation of the compounds described herein.
The processes described herein can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1H or 13C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatography such as high pressure liquid chromatograpy (HPLC), gas chromatography (GC), gel-permeation chromatography (GPC), or thin layer chromatography (TLC).
Preparation of the compounds can involve protection and deprotection of various chemical groups. The need for protection and deprotection and the selection of appropriate protecting groups can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in Greene, et al., Protective Groups in Organic Synthesis, 2d. Ed. (Wiley & Sons, 1991), the entire disclosure of which is incorporated by reference herein for all purposes.
The reactions or the processes described herein can be carried out in suitable solvents that can be readily selected by one skilled in the art of organic synthesis. Suitable solvents typically are substantially nonreactive with the reactants, intermediates, and/or products at the temperatures at which the reactions are carried out, i.e., temperatures that can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected.
In the following Schemes, R1 is the substitutent as defined elsewhere herein for (I), and/or a protected form and/or a derivative thereof, which can be deprotected and/or derivatized according to methods known in the art to generate a group R1 as defined elsewhere herein for (I).
In certain embodiments, a compound of the disclosure can be prepared, for example, according to the illustrative synthetic methods outlined in Scheme I:
In certain embodiments, a compound of the disclosure can be prepared, for example, according to the illustrative synthetic methods outlined in Scheme II.
In certain embodiments, a compound of the disclosure can be prepared, for example, according to the illustrative synthetic methods outlined in Scheme III:
In certain embodiments, a compound of the disclosure can be prepared, for example, according to the illustrative synthetic methods outlined in Scheme IV:
In certain embodiments, a compound of the disclosure can be prepared, for example, according to the illustrative synthetic methods outlined in Scheme V:
In certain embodiments, a compound of the disclosure can be prepared, for example, according to the illustrative synthetic methods outlined in Scheme VI:
In certain embodiments, a compound of the disclosure can be prepared, for example, according to the illustrative synthetic methods outlined in Scheme VII:
The disclosure provides a method of treating, ameliorating, and/or preventing hepatitis virus infection in a subject. In certain embodiments, the virus comprises hepatitis B virus (HBV). In other embodiments, the virus comprises hepatitis D virus (HDV). In yet other embodiments, the virus comprises HBV and HDV. In yet other embodiments, the method comprises administering to the subject in need thereof a therapeutically effective amount of at least one compound of the disclosure. In yet other embodiments, the compound of the disclosure is the only antiviral agent administered to the subject. In yet other embodiments, the at least one compound is administered to the subject in a pharmaceutically acceptable composition. In yet other embodiments, the subject is further administered at least one additional agent useful for treating the hepatitis virus infection. In yet other embodiments, the at least one additional agent comprises at least one selected from the group consisting of reverse transcriptase inhibitors, capsid inhibitors, cccDNA formation inhibitors, RNA destabilizers, oligomeric nucleotides targeted against the HBV genome, immunostimulators, and GalNAc-siRNA conjugates targeted against an HBV gene transcript.
In yet other embodiments, the subject is co-administered the at least one compound and the at least one additional agent. In yet other embodiments, the at least one compound and the at least one additional agent are coformulated.
The disclosure further provides a method of inhibiting and/or reducing HBV surface antigen (HBsAg) secretion either directly or indirectly in a subject. The disclosure further provides a method of reducing or minimizing levels of HBsAg in an HBV-infected subject. The disclosure further provides a method of reducing or minimizing levels of HBeAg in an HBV-infected subject. The disclosure further provides a method of reducing or minimizing levels of hepatitis B core protein in an HBV-infected subject. The disclosure further provides a method of reducing or minimizing levels of pg RNA in an HBV-infected subject.
In certain embodiments, the method comprises administering to the subject in need thereof a therapeutically effective amount of at least one compound of the disclosure. In other embodiments, the at least one compound is administered to the subject in a pharmaceutically acceptable composition. In yet other embodiments, the compound of the disclosure is the only antiviral agent administered to the subject. In yet other embodiments, the subject is further administered at least one additional agent useful for treating HBV infection. In yet other embodiments, the at least one additional agent comprises at least one selected from the group consisting of reverse transcriptase inhibitors, capsid inhibitors, cccDNA formation inhibitors, RNA destabilizers, oligomeric nucleotides targeted against the HBV genome, immunostimulators, and GalNAc-siRNA conjugates targeted against an HBV gene transcript. In yet other embodiments, the subject is co-administered the at least one compound and the at least one additional agent. In yet other embodiments, the at least one compound and the at least one additional agent are coformulated.
In certain embodiments, the subject is a subject in need thereof.
In certain embodiments, the subject is a mammal. In other embodiments, the mammal is a human.
The disclosure provides pharmaceutical compositions comprising at least one compound of the disclosure or a salt or solvate thereof, which are useful to practice methods of the disclosure. Such a pharmaceutical composition may consist of at least one compound of the disclosure or a salt or solvate thereof, in a form suitable for administration to a subject, or the pharmaceutical composition may comprise at least one compound of the disclosure or a salt or solvate thereof, and one or more pharmaceutically acceptable carriers, one or more additional ingredients, or some combination of these. At least one compound of the disclosure may be present in the pharmaceutical composition in the form of a physiologically acceptable salt, such as in combination with a physiologically acceptable cation or anion, as is well known in the art.
In certain embodiments, the pharmaceutical compositions useful for practicing the method of the disclosure may be administered to deliver a dose of between 1 ng/kg/day and 100 mg/kg/day. In other embodiments, the pharmaceutical compositions useful for practicing the disclosure may be administered to deliver a dose of between 1 ng/kg/day and 1,000 mg/kg/day.
The relative amounts of the active ingredient, the pharmaceutically acceptable carrier, and any additional ingredients in a pharmaceutical composition of the disclosure will vary, depending upon the identity, size, and condition of the subject treated and further depending upon the route by which the composition is to be administered. By way of example, the composition may comprise between 0.1% and 100% (w/w) active ingredient.
Pharmaceutical compositions that are useful in the methods of the disclosure may be suitably developed for nasal, inhalational, oral, rectal, vaginal, pleural, peritoneal, parenteral, topical, transdermal, pulmonary, intranasal, buccal, ophthalmic, epidural, intrathecal, intravenous or another route of administration. A composition useful within the methods of the disclosure may be directly administered to the brain, the brainstem, or any other part of the central nervous system of a mammal or bird. Other contemplated formulations include projected nanoparticles, microspheres, liposomal preparations, coated particles, polymer conjugates, resealed erythrocytes containing the active ingredient, and immunologically-based formulations.
In certain embodiments, the compositions of the disclosure are part of a pharmaceutical matrix, which allows for manipulation of insoluble materials and improvement of the bioavailability thereof, development of controlled or sustained release products, and generation of homogeneous compositions. By way of example, a pharmaceutical matrix may be prepared using hot melt extrusion, solid solutions, solid dispersions, size reduction technologies, molecular complexes (e.g., cyclodextrins, and others), microparticulate, and particle and formulation coating processes. Amorphous or crystalline phases may be used in such processes.
The route(s) of administration will be readily apparent to the skilled artisan and will depend upon any number of factors including the type and severity of the disease being treated, the type and age of the veterinary or human patient being treated, and the like.
The formulations of the pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology and pharmaceutics. In general, such preparatory methods include the step of bringing the active ingredient into association with a carrier or one or more other accessory ingredients, and then, if necessary or desirable, shaping or packaging the product into a desired single-dose or multi-dose unit.
As used herein, a “unit dose” is a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient that would be administered to a subject or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage. The unit dosage form may be for a single daily dose or one of multiple daily doses (e.g., about 1 to 4 or more times per day). When multiple daily doses are used, the unit dosage form may be the same or different for each dose.
Although the descriptions of pharmaceutical compositions provided herein are principally directed to pharmaceutical compositions suitable for ethical administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and perform such modification with merely ordinary, if any, experimentation. Subjects to which administration of the pharmaceutical compositions of the disclosure is contemplated include, but are not limited to, humans and other primates, mammals including commercially relevant mammals such as cattle, pigs, horses, sheep, cats, and dogs.
In certain embodiments, the compositions of the disclosure are formulated using one or more pharmaceutically acceptable excipients or carriers. In certain embodiments, the pharmaceutical compositions of the disclosure comprise a therapeutically effective amount of at least one compound of the disclosure and a pharmaceutically acceptable carrier.
Pharmaceutically acceptable carriers, which are useful, include, but are not limited to, glycerol, water, saline, ethanol, recombinant human albumin (e.g., RECOMBUMIN®), solubilized gelatins (e.g., GELOFUSINE®), and other pharmaceutically acceptable salt solutions such as phosphates and salts of organic acids. Examples of these and other pharmaceutically acceptable carriers are described in Remington's Pharmaceutical Sciences (1991, Mack Publication Co., New Jersey).
The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), recombinant human albumin, solubilized gelatins, suitable mixtures thereof, and vegetable oils. The proper fluidity may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms may be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, isotonic agents, for example, sugars, sodium chloride, or polyalcohols such as mannitol and sorbitol, are included in the composition. Prolonged absorption of the injectable compositions may be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate or gelatin.
Formulations may be employed in admixtures with conventional excipients, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for oral, parenteral, nasal, inhalational, intravenous, subcutaneous, transdermal enteral, or any other suitable mode of administration, known to the art. The pharmaceutical preparations may be sterilized and if desired mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure buffers, coloring, flavoring and/or fragrance-conferring substances and the like. They may also be combined where desired with other active agents, e.g., other analgesic, anxiolytics or hypnotic agents. As used herein, “additional ingredients” include, but are not limited to, one or more ingredients that may be used as a pharmaceutical carrier.
The composition of the disclosure may comprise a preservative from about 0.005% to 2.0% by total weight of the composition. The preservative is used to prevent spoilage in the case of exposure to contaminants in the environment. Examples of preservatives useful in accordance with the disclosure include but are not limited to those selected from the group consisting of benzyl alcohol, sorbic acid, parabens, imidurea and combinations thereof. One such preservative is a combination of about 0.5% to 2.0% benzyl alcohol and 0.05% to 0.5% sorbic acid.
The composition may include an antioxidant and a chelating agent which inhibit the degradation of the compound. Antioxidants for some compounds are BHT, BHA, alpha-tocopherol and ascorbic acid in the exemplary range of about 0.01% to 0.3%, or BHT in the range of 0.03% to 0.1% by weight by total weight of the composition. The chelating agent may be present in an amount of from 0.01% to 0.5% by weight by total weight of the composition. Exemplary chelating agents include edetate salts (e.g. disodium edetate) and citric acid in the weight range of about 0.01% to 0.20%, or in the range of 0.02% to 0.10% by weight by total weight of the composition. The chelating agent is useful for chelating metal ions in the composition that may be detrimental to the shelf life of the formulation. While BHT and disodium edetate are exemplary antioxidant and chelating agent, respectively, for some compounds, other suitable and equivalent antioxidants and chelating agents may be substituted therefore as would be known to those skilled in the art.
Liquid suspensions may be prepared using conventional methods to achieve suspension of the active ingredient in an aqueous or oily vehicle. Aqueous vehicles include, for example, water, and isotonic saline. Oily vehicles include, for example, almond oil, oily esters, ethyl alcohol, vegetable oils such as arachis, olive, sesame, or coconut oil, fractionated vegetable oils, and mineral oils such as liquid paraffin. Liquid suspensions may further comprise one or more additional ingredients including, but not limited to, suspending agents, dispersing or wetting agents, emulsifying agents, demulcents, preservatives, buffers, salts, flavorings, coloring agents, and sweetening agents. Oily suspensions may further comprise a thickening agent. Known suspending agents include, but are not limited to, sorbitol syrup, hydrogenated edible fats, sodium alginate, polyvinylpyrrolidone, gum tragacanth, gum acacia, and cellulose derivatives such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl cellulose. Known dispersing or wetting agents include, but are not limited to, naturally-occurring phosphatides such as lecithin, condensation products of an alkylene oxide with a fatty acid, with a long chain aliphatic alcohol, with a partial ester derived from a fatty acid and a hexitol, or with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene stearate, heptadecaethyleneoxycetanol, polyoxyethylene sorbitol monooleate, and polyoxyethylene sorbitan monooleate, respectively). Known emulsifying agents include, but are not limited to, lecithin, acacia, and ionic or non ionic surfactants. Known preservatives include, but are not limited to, methyl, ethyl, or n-propyl para-hydroxybenzoates, ascorbic acid, and sorbic acid. Known sweetening agents include, for example, glycerol, propylene glycol, sorbitol, sucrose, and saccharin.
Liquid solutions of the active ingredient in aqueous or oily solvents may be prepared in substantially the same manner as liquid suspensions, the primary difference being that the active ingredient is dissolved, rather than suspended in the solvent. As used herein, an “oily” liquid is one which comprises a carbon-containing liquid molecule and which exhibits a less polar character than water. Liquid solutions of the pharmaceutical composition of the disclosure may comprise each of the components described with regard to liquid suspensions, it being understood that suspending agents will not necessarily aid dissolution of the active ingredient in the solvent. Aqueous solvents include, for example, water, and isotonic saline. Oily solvents include, for example, almond oil, oily esters, ethyl alcohol, vegetable oils such as arachis, olive, sesame, or coconut oil, fractionated vegetable oils, and mineral oils such as liquid paraffin.
Powdered and granular formulations of a pharmaceutical preparation of the disclosure may be prepared using known methods. Such formulations may be administered directly to a subject, used, for example, to form tablets, to fill capsules, or to prepare an aqueous or oily suspension or solution by addition of an aqueous or oily vehicle thereto. Each of these formulations may further comprise one or more of dispersing or wetting agent, a suspending agent, ionic and nonionic surfactants, and a preservative. Additional excipients, such as fillers and sweetening, flavoring, or coloring agents, may also be included in these formulations.
A pharmaceutical composition of the disclosure may also be prepared, packaged, or sold in the form of oil-in-water emulsion or a water-in-oil emulsion. The oily phase may be a vegetable oil such as olive or arachis oil, a mineral oil such as liquid paraffin, or a combination of these. Such compositions may further comprise one or more emulsifying agents such as naturally occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soybean or lecithin phosphatide, esters or partial esters derived from combinations of fatty acids and hexitol anhydrides such as sorbitan monooleate, and condensation products of such partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. These emulsions may also contain additional ingredients including, for example, sweetening or flavoring agents.
Methods for impregnating or coating a material with a chemical composition are known in the art, and include, but are not limited to methods of depositing or binding a chemical composition onto a surface, methods of incorporating a chemical composition into the structure of a material during the synthesis of the material (i.e., such as with a physiologically degradable material), and methods of absorbing an aqueous or oily solution or suspension into an absorbent material, with or without subsequent drying. Methods for mixing components include physical milling, the use of pellets in solid and suspension formulations and mixing in a transdermal patch, as known to those skilled in the art.
The regimen of administration may affect what constitutes an effective amount. The therapeutic formulations may be administered to the patient either prior to or after the onset of a disease or disorder. Further, several divided dosages, as well as staggered dosages may be administered daily or sequentially, or the dose may be continuously infused, or may be a bolus injection. Further, the dosages of the therapeutic formulations may be proportionally increased or decreased as indicated by the exigencies of the therapeutic or prophylactic situation.
Administration of the compositions of the present disclosure to a patient, such as a mammal, such as a human, may be carried out using known procedures, at dosages and for periods of time effective to treat a disease or disorder contemplated herein. An effective amount of the therapeutic compound necessary to achieve a therapeutic effect may vary according to factors such as the activity of the particular compound employed; the time of administration; the rate of excretion of the compound; the duration of the treatment; other drugs, compounds or materials used in combination with the compound; the state of the disease or disorder, age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well-known in the medical arts. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. A non-limiting example of an effective dose range for a therapeutic compound of the disclosure is from about 0.01 mg/kg to 100 mg/kg of body weight/per day. One of ordinary skill in the art would be able to study the relevant factors and make the determination regarding the effective amount of the therapeutic compound without undue experimentation.
The compound may be administered to an animal as frequently as several times daily, or it may be administered less frequently, such as once a day, once a week, once every two weeks, once a month, or even less frequently, such as once every several months or even once a year or less. It is understood that the amount of compound dosed per day may be administered, in non-limiting examples, every day, every other day, every 2 days, every 3 days, every 4 days, or every 5 days. For example, with every other day administration, a 5 mg per day dose may be initiated on Monday with a first subsequent 5 mg per day dose administered on Wednesday, a second subsequent 5 mg per day dose administered on Friday, and so on. The frequency of the dose is readily apparent to the skilled artisan and depends upon a number of factors, such as, but not limited to, type and severity of the disease being treated, and type and age of the animal.
Actual dosage levels of the active ingredients in the pharmaceutical compositions of this disclosure may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
A medical doctor, e.g., physician or veterinarian, having ordinary skill in the art may readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the disclosure employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
In particular embodiments, it is especially advantageous to formulate the compound in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the patients to be treated; each unit containing a predetermined quantity of therapeutic compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical vehicle. The dosage unit forms of the disclosure are dictated by and directly dependent on (a) the unique characteristics of the therapeutic compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding/formulating such a therapeutic compound for the treatment of a disease or disorder in a patient.
In certain embodiments, the compositions of the disclosure are administered to the patient in dosages that range from one to five times per day or more. In other embodiments, the compositions of the disclosure are administered to the patient in range of dosages that include, but are not limited to, once every day, every two days, every three days to once a week, and once every two weeks. It will be readily apparent to one skilled in the art that the frequency of administration of the various combination compositions of the disclosure will vary from subject to subject depending on many factors including, but not limited to, age, disease or disorder to be treated, gender, overall health, and other factors. Thus, the disclosure should not be construed to be limited to any particular dosage regime and the precise dosage and composition to be administered to any patient will be determined by the attending physician taking all other factors about the patient into account.
Compounds of the disclosure for administration may be in the range of from about 1 μg to about 7,500 mg, about 20 μg to about 7,000 mg, about 40 μg to about 6,500 mg, about 80 μg to about 6,000 mg, about 100 μg to about 5,500 mg, about 200 μg to about 5,000 mg, about 400 μg to about 4,000 mg, about 800 μg to about 3,000 mg, about 1 mg to about 2,500 mg, about 2 mg to about 2,000 mg, about 5 mg to about 1,000 mg, about 10 mg to about 750 mg, about 20 mg to about 600 mg, about 30 mg to about 500 mg, about 40 mg to about 400 mg, about 50 mg to about 300 mg, about 60 mg to about 250 mg, about 70 mg to about 200 mg, about 80 mg to about 150 mg, and any and all whole or partial increments there-in-between.
In some embodiments, the dose of a compound of the disclosure is from about 0.5 μg and about 5,000 mg. In some embodiments, a dose of a compound of the disclosure used in compositions described herein is less than about 5,000 mg, or less than about 4,000 mg, or less than about 3,000 mg, or less than about 2,000 mg, or less than about 1,000 mg, or less than about 800 mg, or less than about 600 mg, or less than about 500 mg, or less than about 200 mg, or less than about 50 mg. Similarly, in some embodiments, a dose of a second compound as described herein is less than about 1,000 mg, or less than about 800 mg, or less than about 600 mg, or less than about 500 mg, or less than about 400 mg, or less than about 300 mg, or less than about 200 mg, or less than about 100 mg, or less than about 50 mg, or less than about 40 mg, or less than about 30 mg, or less than about 25 mg, or less than about 20 mg, or less than about 15 mg, or less than about 10 mg, or less than about 5 mg, or less than about 2 mg, or less than about 1 mg, or less than about 0.5 mg, and any and all whole or partial increments thereof.
In certain embodiments, the present disclosure is directed to a packaged pharmaceutical composition comprising a container holding a therapeutically effective amount of a compound of the disclosure, alone or in combination with a second pharmaceutical agent; and instructions for using the compound to treat, prevent, or reduce one or more symptoms of a disease or disorder in a patient.
The term “container” includes any receptacle for holding the pharmaceutical composition or for managing stability or water uptake. For example, in certain embodiments, the container is the packaging that contains the pharmaceutical composition, such as liquid (solution and suspension), semisolid, lyophilized solid, solution and powder or lyophilized formulation present in dual chambers. In other embodiments, the container is not the packaging that contains the pharmaceutical composition, i.e., the container is a receptacle, such as a box or vial that contains the packaged pharmaceutical composition or unpackaged pharmaceutical composition and the instructions for use of the pharmaceutical composition. Moreover, packaging techniques are well known in the art. It should be understood that the instructions for use of the pharmaceutical composition may be contained on the packaging containing the pharmaceutical composition, and as such the instructions form an increased functional relationship to the packaged product. However, it should be understood that the instructions may contain information pertaining to the compound's ability to perform its intended function, e.g., treating, preventing, or reducing a disease or disorder in a patient.
Routes of administration of any of the compositions of the disclosure include inhalational, oral, nasal, rectal, parenteral, sublingual, transdermal, transmucosal (e.g., sublingual, lingual, (trans)buccal, (trans)urethral, vaginal (e.g., trans- and perivaginally), (intra)nasal, and (trans)rectal), intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, epidural, intrapleural, intraperitoneal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical administration.
Suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel caps, troches, emulsions, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry powder or aerosolized formulations for inhalation, compositions and formulations for intravesical administration and the like. It should be understood that the formulations and compositions that would be useful in the present disclosure are not limited to the particular formulations and compositions that are described herein.
For oral application, particularly suitable are tablets, dragees, liquids, drops, capsules, caplets and gelcaps. Other formulations suitable for oral administration include, but are not limited to, a powdered or granular formulation, an aqueous or oily suspension, an aqueous or oily solution, a paste, a gel, toothpaste, a mouthwash, a coating, an oral rinse, or an emulsion. The compositions intended for oral use may be prepared according to any method known in the art and such compositions may contain one or more agents selected from the group consisting of inert, non-toxic, generally recognized as safe (GRAS) pharmaceutically excipients which are suitable for the manufacture of tablets. Such excipients include, for example an inert diluent such as lactose; granulating and disintegrating agents such as cornstarch; binding agents such as starch; and lubricating agents such as magnesium stearate.
Tablets may be non-coated or they may be coated using known methods to achieve delayed disintegration in the gastrointestinal tract of a subject, thereby providing sustained release and absorption of the active ingredient. By way of example, a material such as glyceryl monostearate or glyceryl distearate may be used to coat tablets. Further by way of example, tablets may be coated using methods described in U.S. Pat. Nos. 4,256,108; 4,160,452; and U.S. Pat. No. 4,265,874 to form osmotically controlled release tablets. Tablets may further comprise a sweetening agent, a flavoring agent, a coloring agent, a preservative, or some combination of these in order to provide for pharmaceutically elegant and palatable preparation. Hard capsules comprising the active ingredient may be made using a physiologically degradable composition, such as gelatin. The capsules comprise the active ingredient, and may further comprise additional ingredients including, for example, an inert solid diluent such as calcium carbonate, calcium phosphate, or kaolin.
Hard capsules comprising the active ingredient may be made using a physiologically degradable composition, such as gelatin. Such hard capsules comprise the active ingredient, and may further comprise additional ingredients including, for example, an inert solid diluent such as calcium carbonate, calcium phosphate, or kaolin.
Soft gelatin capsules comprising the active ingredient may be made using a physiologically degradable composition, such as gelatin from animal-derived collagen or from a hypromellose, a modified form of cellulose, and manufactured using optional mixtures of gelatin, water and plasticizers such as sorbitol or glycerol. Such soft capsules comprise the active ingredient, which may be mixed with water or an oil medium such as peanut oil, liquid paraffin, or olive oil.
For oral administration, the compounds of the disclosure may be in the form of tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents; fillers; lubricants; disintegrates; or wetting agents. If desired, the tablets may be coated using suitable methods and coating materials such as OPADRY® film coating systems available from Colorcon, West Point, Pa. (e.g., OPADRY® OY Type, OYC Type, Organic Enteric OY-P Type, Aqueous Enteric OY-A Type, OY-PM Type and OPADRY® White, 32K18400). It is understood that similar type of film coating or polymeric products from other companies may be used.
A tablet comprising the active ingredient may, for example, be made by compressing or molding the active ingredient, optionally with one or more additional ingredients. Compressed tablets may be prepared by compressing, in a suitable device, the active ingredient in a free-flowing form such as a powder or granular preparation, optionally mixed with one or more of a binder, a lubricant, an excipient, a surface-active agent, and a dispersing agent. Molded tablets may be made by molding, in a suitable device, a mixture of the active ingredient, a pharmaceutically acceptable carrier, and at least sufficient liquid to moisten the mixture. Pharmaceutically acceptable excipients used in the manufacture of tablets include, but are not limited to, inert diluents, granulating and disintegrating agents, binding agents, and lubricating agents. Known dispersing agents include, but are not limited to, potato starch and sodium starch glycolate. Known surface-active agents include, but are not limited to, sodium lauryl sulphate. Known diluents include, but are not limited to, calcium carbonate, sodium carbonate, lactose, microcrystalline cellulose, calcium phosphate, calcium hydrogen phosphate, and sodium phosphate. Known granulating and disintegrating agents include, but are not limited to, corn starch and alginic acid. Known binding agents include, but are not limited to, gelatin, acacia, pre-gelatinized maize starch, polyvinylpyrrolidone, and hydroxypropyl methylcellulose. Known lubricating agents include, but are not limited to, magnesium stearate, stearic acid, silica, and talc.
Granulating techniques are well known in the pharmaceutical art for modifying starting powders or other particulate materials of an active ingredient. The powders are typically mixed with a binder material into larger permanent free-flowing agglomerates or granules referred to as a “granulation.” For example, solvent-using “wet” granulation processes are generally characterized in that the powders are combined with a binder material and moistened with water or an organic solvent under conditions resulting in the formation of a wet granulated mass from which the solvent must then be evaporated.
Melt granulation generally consists in the use of materials that are solid or semi-solid at room temperature (i.e., having a relatively low softening or melting point range) to promote granulation of powdered or other materials, essentially in the absence of added water or other liquid solvents. The low melting solids, when heated to a temperature in the melting point range, liquefy to act as a binder or granulating medium. The liquefied solid spreads itself over the surface of powdered materials with which it is contacted, and on cooling, forms a solid granulated mass in which the initial materials are bound together. The resulting melt granulation may then be provided to a tablet press or be encapsulated for preparing the oral dosage form. Melt granulation improves the dissolution rate and bioavailability of an active (i.e., drug) by forming a solid dispersion or solid solution.
U.S. Pat. No. 5,169,645 discloses directly compressible wax-containing granules having improved flow properties. The granules are obtained when waxes are admixed in the melt with certain flow improving additives, followed by cooling and granulation of the admixture. In certain embodiments, only the wax itself melts in the melt combination of the wax(es) and additives(s), and in other cases both the wax(es) and the additives(s) will melt.
The present disclosure also includes a multi-layer tablet comprising a layer providing for the delayed release of one or more compounds useful within the methods of the disclosure, and a further layer providing for the immediate release of one or more compounds useful within the methods of the disclosure. Using a wax/pH-sensitive polymer mix, a gastric insoluble composition may be obtained in which the active ingredient is entrapped, ensuring its delayed release.
Liquid preparation for oral administration may be in the form of solutions, syrups or suspensions. The liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agent (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl para-hydroxy benzoates or sorbic acid). Liquid formulations of a pharmaceutical composition of the disclosure which are suitable for oral administration may be prepared, packaged, and sold either in liquid form or in the form of a dry product intended for reconstitution with water or another suitable vehicle prior to use.
As used herein, “parenteral administration” of a pharmaceutical composition includes any route of administration characterized by physical breaching of a tissue of a subject and administration of the pharmaceutical composition through the breach in the tissue. Parenteral administration thus includes, but is not limited to, administration of a pharmaceutical composition by injection of the composition, by application of the composition through a surgical incision, by application of the composition through a tissue-penetrating non-surgical wound, and the like. In particular, parenteral administration is contemplated to include, but is not limited to, subcutaneous, intravenous, intraperitoneal, intramuscular, intrasternal injection, and kidney dialytic infusion techniques.
Formulations of a pharmaceutical composition suitable for parenteral administration comprise the active ingredient combined with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline. Such formulations may be prepared, packaged, or sold in a form suitable for bolus administration or for continuous administration. Injectable formulations may be prepared, packaged, or sold in unit dosage form, such as in ampules or in multidose containers containing a preservative. Injectable formulations may also be prepared, packaged, or sold in devices such as patient-controlled analgesia (PCA) devices. Formulations for parenteral administration include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations. Such formulations may further comprise one or more additional ingredients including, but not limited to, suspending, stabilizing, or dispersing agents. In one embodiment of a formulation for parenteral administration, the active ingredient is provided in dry (i.e., powder or granular) form for reconstitution with a suitable vehicle (e.g., sterile pyrogen-free water) prior to parenteral administration of the reconstituted composition.
The pharmaceutical compositions may be prepared, packaged, or sold in the form of a sterile injectable aqueous or oily suspension or solution. This suspension or solution may be formulated according to the known art, and may comprise, in addition to the active ingredient, additional ingredients such as the dispersing agents, wetting agents, or suspending agents described herein. Such sterile injectable formulations may be prepared using a non-toxic parenterally acceptable diluent or solvent, such as water or 1,3-butanediol, for example. Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic mono- or di-glycerides. Other parentally-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form in a recombinant human albumin, a fluidized gelatin, in a liposomal preparation, or as a component of a biodegradable polymer system. Compositions for sustained release or implantation may comprise pharmaceutically acceptable polymeric or hydrophobic materials such as an emulsion, an ion exchange resin, a sparingly soluble polymer, or a sparingly soluble salt.
An obstacle for topical administration of pharmaceuticals is the stratum corneum layer of the epidermis. The stratum corneum is a highly resistant layer comprised of protein, cholesterol, sphingolipids, free fatty acids and various other lipids, and includes cornified and living cells. One of the factors that limit the penetration rate (flux) of a compound through the stratum corneum is the amount of the active substance that can be loaded or applied onto the skin surface. The greater the amount of active substance which is applied per unit of area of the skin, the greater the concentration gradient between the skin surface and the lower layers of the skin, and in turn the greater the diffusion force of the active substance through the skin. Therefore, a formulation containing a greater concentration of the active substance is more likely to result in penetration of the active substance through the skin, and more of it, and at a more consistent rate, than a formulation having a lesser concentration, all other things being equal.
Formulations suitable for topical administration include, but are not limited to, liquid or semi-liquid preparations such as liniments, lotions, oil-in-water or water-in-oil emulsions such as creams, ointments or pastes, and solutions or suspensions. Topically administrable formulations may, for example, comprise from about 1% to about 10% (w/w) active ingredient, although the concentration of the active ingredient may be as high as the solubility limit of the active ingredient in the solvent. Formulations for topical administration may further comprise one or more of the additional ingredients described herein.
Enhancers of permeation may be used. These materials increase the rate of penetration of drugs across the skin. Typical enhancers in the art include ethanol, glycerol monolaurate, PGML (polyethylene glycol monolaurate), dimethylsulfoxide, and the like. Other enhancers include oleic acid, oleyl alcohol, ethoxydiglycol, laurocapram, alkanecarboxylic acids, dimethylsulfoxide, polar lipids, or N-methyl-2-pyrrolidone.
One acceptable vehicle for topical delivery of some of the compositions of the disclosure may contain liposomes. The composition of the liposomes and their use are known in the art (i.e., U.S. Pat. No. 6,323,219).
In alternative embodiments, the topically active pharmaceutical composition may be optionally combined with other ingredients such as adjuvants, anti-oxidants, chelating agents, surfactants, foaming agents, wetting agents, emulsifying agents, viscosifiers, buffering agents, preservatives, and the like. In other embodiments, a permeation or penetration enhancer is included in the composition and is effective in improving the percutaneous penetration of the active ingredient into and through the stratum corneum with respect to a composition lacking the permeation enhancer. Various permeation enhancers, including oleic acid, oleyl alcohol, ethoxydiglycol, laurocapram, alkanecarboxylic acids, dimethylsulfoxide, polar lipids, or N-methyl-2-pyrrolidone, are known to those of skill in the art. In another aspect, the composition may further comprise a hydrotropic agent, which functions to increase disorder in the structure of the stratum corneum, and thus allows increased transport across the stratum corneum. Various hydrotropic agents such as isopropyl alcohol, propylene glycol, or sodium xylene sulfonate, are known to those of skill in the art.
The topically active pharmaceutical composition should be applied in an amount effective to affect desired changes. As used herein “amount effective” shall mean an amount sufficient to cover the region of skin surface where a change is desired. An active compound should be present in the amount of from about 0.0001% to about 15% by weight volume of the composition. For example, it should be present in an amount from about 0.0005% to about 5% of the composition; for example, it should be present in an amount of from about 0.001% to about 1% of the composition. Such compounds may be synthetically- or naturally derived.
A pharmaceutical composition of the disclosure may be prepared, packaged, or sold in a formulation suitable for buccal administration. Such formulations may, for example, be in the form of tablets or lozenges made using conventional methods, and may contain, for example, 0.1 to 20% (w/w) of the active ingredient, the balance comprising an orally dissolvable or degradable composition and, optionally, one or more of the additional ingredients described herein. Alternately, formulations suitable for buccal administration may comprise a powder or an aerosolized or atomized solution or suspension comprising the active ingredient. Such powdered, aerosolized, or aerosolized formulations, when dispersed, may have an average particle or droplet size in the range from about 0.1 to about 200 nanometers, and may further comprise one or more of the additional ingredients described herein. The examples of formulations described herein are not exhaustive and it is understood that the disclosure includes additional modifications of these and other formulations not described herein, but which are known to those of skill in the art.
A pharmaceutical composition of the disclosure may be prepared, packaged, or sold in a formulation suitable for rectal administration. Such a composition may be in the form of, for example, a suppository, a retention enema preparation, and a solution for rectal or colonic irrigation.
Suppository formulations may be made by combining the active ingredient with a non-irritating pharmaceutically acceptable excipient which is solid at ordinary room temperature (i.e., about 20° C.) and which is liquid at the rectal temperature of the subject (i.e., about 37° C. in a healthy human). Suitable pharmaceutically acceptable excipients include, but are not limited to, cocoa butter, polyethylene glycols, and various glycerides. Suppository formulations may further comprise various additional ingredients including, but not limited to, antioxidants, and preservatives.
Retention enema preparations or solutions for rectal or colonic irrigation may be made by combining the active ingredient with a pharmaceutically acceptable liquid carrier. As is well known in the art, enema preparations may be administered using, and may be packaged within, a delivery device adapted to the rectal anatomy of the subject. Enema preparations may further comprise various additional ingredients including, but not limited to, antioxidants, and preservatives.
Additional dosage forms of this disclosure include dosage forms as described in U.S. Pat. Nos. 6,340,475, 6,488,962, 6,451,808, 5,972,389, 5,582,837, and 5,007,790. Additional dosage forms of this disclosure also include dosage forms as described in U.S. Patent Applications Nos. 20030147952, 20030104062, 20030104053, 20030044466, 20030039688, and 20020051820. Additional dosage forms of this disclosure also include dosage forms as described in PCT Applications Nos. WO 03/35041, WO 03/35040, WO 03/35029, WO 03/35177, WO 03/35039, WO 02/96404, WO 02/32416, WO 01/97783, WO 01/56544, WO 01/32217, WO 98/55107, WO 98/11879, WO 97/47285, WO 93/18755, and WO 90/11757.
In certain embodiments, the compositions and/or formulations of the present disclosure may be, but are not limited to, short-term, rapid-offset, as well as controlled, for example, sustained release, delayed release and pulsatile release formulations.
The term sustained release is used in its conventional sense to refer to a drug formulation that provides for gradual release of a drug over an extended period of time, and that may, although not necessarily, result in substantially constant blood levels of a drug over an extended time period. The period of time may be as long as a month or more and should be a release which is longer that the same amount of agent administered in bolus form.
For sustained release, the compounds may be formulated with a suitable polymer or hydrophobic material which provides sustained release properties to the compounds. As such, the compounds for use the method of the disclosure may be administered in the form of microparticles, for example, by injection or in the form of wafers or discs by implantation.
In certain embodiments of the disclosure, the compounds useful within the disclosure are administered to a subject, alone or in combination with another pharmaceutical agent, using a sustained release formulation.
The term delayed release is used herein in its conventional sense to refer to a drug formulation that provides for an initial release of the drug after some delay following drug administration and that may, although not necessarily, include a delay of from about 10 minutes up to about 12 hours.
The term pulsatile release is used herein in its conventional sense to refer to a drug formulation that provides release of the drug in such a way as to produce pulsed plasma profiles of the drug after drug administration.
The term immediate release is used in its conventional sense to refer to a drug formulation that provides for release of the drug immediately after drug administration.
As used herein, short-term refers to any period of time up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, or about 10 minutes and any or all whole or partial increments thereof after drug administration after drug administration.
As used herein, rapid-offset refers to any period of time up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, or about 10 minutes, and any and all whole or partial increments thereof after drug administration.
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures, embodiments, claims, and examples described herein. Such equivalents were considered to be within the scope of this disclosure and covered by the claims appended hereto. For example, it should be understood, that modifications in reaction conditions, including but not limited to reaction times, reaction size/volume, and experimental reagents, such as solvents, catalysts, pressures, atmospheric conditions, e.g., nitrogen atmosphere, and reducing/oxidizing agents, with art-recognized alternatives and using no more than routine experimentation, are within the scope of the present application.
It is to be understood that, wherever values and ranges are provided herein, the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosure. Accordingly, all values and ranges encompassed by these values and ranges are meant to be encompassed within the scope of the present disclosure. Moreover, all values that fall within these ranges, as well as the upper or lower limits of a range of values, are also contemplated by the present application. The description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range and, when appropriate, partial integers of the numerical values within ranges. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.
The following examples further illustrate aspects of the present disclosure. However, they are in no way a limitation of the teachings or disclosure of the present disclosure as set forth herein.
The disclosure is now described with reference to the following Examples. These Examples are provided for the purpose of illustration only, and the disclosure is not limited to these Examples, but rather encompasses all variations that are evident as a result of the teachings provided herein.
The following procedures can be utilized in preparing and/or testing exemplary compounds of the disclosure.
As described herein, “Enantiomer I” refers to the first enantiomer eluded from the chiral column under the specific chiral analytical conditions detailed for examples provided elsewhere herein; and “Enantiomer II” refers to the second enantiomer eluded from the chiral column under the specific chiral analytical conditions detailed for examples provided elsewhere herein. Such nomenclature does not imply or impart any particular relative and/or absolute configuration for these compounds.
To a stirred solution of methyl 2-formyl-4,5-dimethoxy-benzoate (2.42 g, 10.8 mmol) and (S)-tert-butyl-sulphinamide (1.57 g, 13 mmol) in anhydrous dichloromethane (150 mL) under nitrogen at room temperature was added copper(II) sulfate (8.9 g, 55 mmol). The reaction mixture was vigorously stirred at room temperature for 2 days. The reaction mixture was filtered through CELITE®, washed with MeOH (30 mL), and the solvent removed under reduced pressure. The crude residue was purified by normal phase SiO2 chromatography (0-100% EtOAc/hexanes) to give methyl (S,E)-2-(((tert-butylsulfinyl)imino)methyl)-4,5-dimethoxybenzoate as a white solid (3.26 g, 92% yield, m/z: 328 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 9.30 (s, 1H), 7.58 (s, 1H), 7.46 (s, 1H), 3.98 (s, 3H), 3.94 (s, 3H), 3.93 (s, 3H), 1.27 (s, 9H).
To a solution of (S,E)-2-(((tert-butylsulfinyl)imino)methyl)-4,5-dimethoxybenzoate (330 mg, 1.01 mmol) in anhydrous THE (10 mL) under nitrogen at −78° C. was added EtMgBr (3M solution in Et2O, 3 mL, 9 mmol). The reaction mixture was warmed to room temperature over 2 hours. The mixture was cooled to 0° C. and quenched by dropwise addition of saturated aqueous ammonium chloride solution (2 mL). Additional saturated aqueous ammonium chloride solution (10 mL) and dichloromethane (25 mL) were added and the mixture stirred for 10 min. The organic layer was separated, dried over anhydrous sodium sulfate, and the solvent evaporated under reduced pressure. The crude residue was purified by normal phase SiO2 chromatography (0-100% EtOAc/hexanes) to give 3-ethyl-5,6-dimethoxyisoindolin-1-one as a white solid (200 mg, 90% yield, m/z: 322 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 7.29 (s, 1H), 7.07 (br s, 1H), 6.86 (s, 1H), 4.51 (t, J=5.6 Hz, 1H), 3.95 (s, 3H), 3.93 (s, 3H), 2.03-1.96 (m, 1H), 1.73-1.64 (m, 1H), 0.94 (t, J=7.2 Hz, 3H).
A microwave vial with stir bar was charged with 4-chloro-2-pyrimidin-2-yl-pyrimidine (40 mg, 0.21 mmol), 3-ethyl-5,6-dimethoxy-isoindolin-1-one (45 mg, 0.2 mmol), Xantphos (24 mg, 0.04 mmol), tris(dibenzylideneacetone)dipalladium (10 mg, 0.01 mmol), and cesium carbonate (165 mg, 0.51 mmol) in anhydrous dioxane (5 mL). The reaction mixture was degassed with nitrogen for 5 minutes. The vial was sealed and heated at 120° C. for 16 hours. The reaction mixture was filtered, and the filtrate was evaporated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (eluants 0 to 10% methanol in dichloromethane) to give 2-([2,2′-bipyrimidin]-4-yl)-3-ethyl-5,6-dimethoxyisoindolin-1-one as an off-white solid (45 mg, 57% yield, m/z: 378 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 8.98 (d, J=4.8 Hz, 2H), 8.87 (d, J=6.0 Hz, 1H), 8.61 (d, J=6.0 Hz, 1H), 7.41 (t, J=4.8 Hz, 1H), 7.32 (s, 1H), 6.88 (s, 1H), 5.88 (dd, J=5.6, 2.8 Hz, 1H), 3.97 (s, 3H), 3.94 (s, 3H), 2.76-2.68 (m, 1H), 2.10-2.02 (m, 1H), 0.46 (t, J=7.2 Hz, 3H).
A mixture of enantiomers (110 mg) was separated by SFC (supercritical fluid chromatography) on a CHIRALPAK® OD column using liquid CO2 and MeOH to give 3-ethyl-5,6-dimethoxy-2-(2-pyrimidin-2-ylpyrimidin-4-yl)isoindolin-1-one (single enantiomer I) as a white solid (faster eluting enantiomer, 47 mg, 43% yield, m/z: 378 [M+H]+ observed), and 3-ethyl-5,6-dimethoxy-2-(2-pyrimidin-2-ylpyrimidin-4-yl)isoindolin-1-one (single enantiomer II) as a white solid (slower eluting enantiomer, 26 mg, 24% yield, m/z: 378 [M+H]+ observed).
m/z: 378 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 8.98 (d, J=4.8 Hz, 2H), 8.87 (d, J=6.0 Hz, 1H), 8.61 (d, J=6.0 Hz, 1H), 7.41 (t, J=4.8 Hz, 1H), 7.32 (s, 1H), 6.88 (s, 1H), 5.88 (dd, J=5.6, 2.8 Hz, 1H), 3.97 (s, 3H), 3.94 (s, 3H), 2.76-2.68 (m, 1H), 2.10-2.02 (m, 1H), 0.46 (t, J=7.2 Hz, 3H).
m/z: 378 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 8.98 (d, J=4.8 Hz, 2H), 8.87 (d, J=6.0 Hz, 1H), 8.61 (d, J=6.0 Hz, 1H), 7.41 (t, J=4.8 Hz, 1H), 7.32 (s, 1H), 6.88 (s, 1H), 5.88 (dd, J=5.6, 2.8 Hz, 1H), 3.97 (s, 3H), 3.94 (s, 3H), 2.76-2.68 (m, 1H), 2.10-2.02 (m, 1H), 0.46 (t, J=7.2 Hz, 3H).
The following examples were prepared in a similar manner as 2-([2,2′-bipyrimidin]-4-yl)-3-ethyl-5,6-dimethoxyisoindolin-1-one from an appropriately substituted methyl (E)-2-(((tert-butylsulfinyl)imino)methyl)benzoate and a suitable Grignard reagent.
A mixture of enantiomers of 2-([2,2′-bipyrimidin]-4-yl)-3-ethyl-5-methoxy-6-methylisoindolin-1-one (330 mg) was separated by SFC (supercritical fluid chromatography) on a CHIRALCEL® OD column using liquid CO2 and MeOH [0.1% aqueous NH3 as modifier] (67:33) to give 2-([2,2′-bipyrimidin]-4-yl)-3-ethyl-5-methoxy-6-methylisoindolin-1-one (single enantiomer I) as a white solid (faster eluting enantiomer, 89 mg, 27%, m/z: 362 [M+H]+ observed), and of 2-([2,2′-bipyrimidin]-4-yl)-3-ethyl-5-methoxy-6-methylisoindolin-1-one (single enantiomer II) as a white solid (slower eluting enantiomer, 210 mg, 64%, m/z: 362 [M+H]+ observed).
m/z: 362 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.04 (d, J=4.8 Hz, 2H), 8.90 (d, J=5.6 Hz, 1H), 8.53 (d, J=5.6 Hz, 1H), 7.67 (t, J=4.8 Hz, 1H), 7.64 (s, 1H), 7.28 (s, 1H), 5.67 (d, J=2.8 Hz, 1H), 3.94 (s, 3H), 2.82-2.72 (m, 1H), 2.25 (s, 3H), 2.20-2.13 (m, 1H), 0.36 (t, J=7.2 Hz, 3H).
m/z: 362 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.04 (d, J=4.8 Hz, 2H), 8.90 (d, J=5.6 Hz, 1H), 8.53 (d, J=5.6 Hz, 1H), 7.67 (t, J=4.8 Hz, 1H), 7.64 (s, 1H), 7.28 (s, 1H), 5.67 (d, J=2.8 Hz, 1H), 3.94 (s, 3H), 2.82-2.72 (m, 1H), 2.25 (s, 3H), 2.20-2.13 (m, 1H), 0.36 (t, J=7.2 Hz, 3H).
A mixture of enantiomers of 2-([2,2′-bipyrimidin]-4-yl)-6-chloro-3-ethyl-5-methoxyisoindolin-1-one (270 mg) was separated by SFC (supercritical fluid chromatography) on a CHIRALCEL® OD column using liquid CO2 and IPA [0.1% aqueous NH3 as modifier] (45:55) to give 2-([2,2′-bipyrimidin]-4-yl)-6-chloro-3-ethyl-5-methoxyisoindolin-1-one (single enantiomer I) as a white solid (faster eluting enantiomer, 103 mg, 38%, m/z: 382 [M+H]+ observed), and 2-([2,2′-bipyrimidin]-4-yl)-6-chloro-3-ethyl-5-methoxyisoindolin-1-one (single enantiomer II) as a yellow solid (slower eluting enantiomer, 94 mg, 35%, m/z: 382 [M+H]+ observed).
m/z: 382 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.05 (d, J=4.8 Hz, 2H), 8.94 (d, J=6.0 Hz, 1H), 8.53 (d, J=5.6 Hz, 1H), 7.90 (s, 1H), 7.68 (t, J=4.8 Hz, 1H), 7.55 (s, 1H), 5.73 (d, J=2.4 Hz, 1H), 4.02 (s, 3H), 2.84-2.77 (m, 1H), 2.24-2.19 (m, 1H), 0.38 (t, J=7.6 Hz, 3H).
m/z: 382 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.05 (d, J=4.8 Hz, 2H), 8.94 (d, J=6.0 Hz, 1H), 8.53 (d, J=5.6 Hz, 1H), 7.90 (s, 1H), 7.68 (t, J=4.8 Hz, 1H), 7.55 (s, 1H), 5.73 (d, J=2.4 Hz, 1H), 4.02 (s, 3H), 2.84-2.77 (m, 1H), 2.24-2.19 (m, 1H), 0.38 (t, J=7.6 Hz, 3H).
A mixture of enantiomers of 2-([2,2′-bipyrimidin]-4-yl)-6-chloro-3-ethyl-4-fluoroisoindolin-1-one (150 mg) was separated by SFC (supercritical fluid chromatography) on a CHIRALCEL® OD column using liquid CO2 and MeOH [0.1% aqueous NH3 as modifier](60:40) to give 2-([2,2′-bipyrimidin]-4-yl)-6-chloro-3-ethyl-4-fluoroisoindolin-1-one (single enantiomer I) as a white solid (faster eluting enantiomer, 49 mg, 33%, m/z: 370 [M+H]+ observed), and 2-([2,2′-bipyrimidin]-4-yl)-6-chloro-3-ethyl-4-fluoroisoindolin-1-one (single enantiomer II) as a white solid (slower eluting enantiomer, 43 mg, 29%, m/z: 370 [M+H]+ observed).
m/z: 370 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.05 (d, J=4.8 Hz, 2H), 9.00 (d, J=5.6 Hz, 1H), 8.52 (d, J=6.0 Hz, 1H), 7.90 (d, J=9.2 Hz, 1H), 7.83 (s, 1H), 7.68 (t, J=5.2 Hz, 1H), 5.96 (d, J=2.0 Hz, 1H), 2.85-2.74 (m, 1H), 2.16-2.11 (m, 1H), 0.42 (t, J=7.2 Hz, 3H).
m/z: 370 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.05 (d, J=4.8 Hz, 2H), 9.00 (d, J=5.6 Hz, 1H), 8.52 (d, J=6.0 Hz, 1H), 7.90 (d, J=9.2 Hz, 1H), 7.83 (s, 1H), 7.68 (t, J=5.2 Hz, 1H), 5.96 (d, J=2.0 Hz, 1H), 2.85-2.74 (m, 1H), 2.16-2.11 (m, 1H), 0.42 (t, J=7.2 Hz, 3H).
A mixture of enantiomers of 2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(4-methoxyphenyl)isoindolin-1-one (180 mg) was separated by SFC (supercritical fluid chromatography) on a CHIRALCEL® OD column using liquid CO2 and MeOH [0.1% aqueous NH3 as modifier] (50:50) to give 2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(4-methoxyphenyl)isoindolin-1-one (single enantiomer I) as a light yellow solid (faster eluting enantiomer, 83 mg, 45%, m/z: 456 [M+H]+ observed), and 2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(4-methoxyphenyl)isoindolin-1-one (single enantiomer II) as a white solid (slower eluting enantiomer, 77 mg, 43%, m/z: 456 [M+H]+ observed).
m/z: 456 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.05 (d, J=4.8 Hz, 2H), 8.83 (d, J=5.6 Hz, 1H), 8.40 (d, J=5.6 Hz, 1H), 7.67 (t, J=4.8 Hz, 1H), 7.37 (s, 1H), 7.29 (d, J 8.8 Hz, 2H), 6.85 (s, 1H), 6.74 (d, J=8.8 Hz, 2H), 6.60 (s, 1H), 3.89 (s, 3H), 3.75 (s, 3H), 3.63 (s, 3H).
m/z: 456 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.05 (d, J=4.8 Hz, 2H), 8.83 (d, J=5.6 Hz, 1H), 8.40 (d, J=5.6 Hz, 1H), 7.67 (t, J=4.8 Hz, 1H), 7.37 (s, 1H), 7.29 (d, J 8.8 Hz, 2H), 6.85 (s, 1H), 6.74 (d, J=8.8 Hz, 2H), 6.60 (s, 1H), 3.89 (s, 3H), 3.75 (s, 3H), 3.63 (s, 3H).
A mixture of enantiomers of 2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(3-methoxyphenyl)isoindolin-1-one (210 mg) was separated by SFC (supercritical fluid chromatography) on a CHIRALCEL® OD column using liquid CO2 and MeOH [0.1% aqueous NH3 as modifier] (47:53) to give 2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(3-methoxyphenyl)isoindolin-1-one (single enantiomer I) as a white solid (faster eluting enantiomer, 81 mg, 39%, m/z: 456 [M+H]+ observed), and 2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(3-methoxyphenyl)isoindolin-1-one (single enantiomer II) as a white solid (slower eluting enantiomer, 47 mg, 22%, m/z: 456 [M+H]+ observed).
m/z: 456 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.02 (d, J=4.8 Hz, 2H), 8.86 (d, J=6.0 Hz, 1H), 8.44 (d, J=6.0 Hz, 1H), 7.66 (t, J=4.8 Hz, 1H), 7.39 (s, 1H), 7.10 (t, J=7.6 Hz, 2H), 6.92 (s, 1H), 6.74-6.71 (m, 2H), 6.62 (s, 1H), 3.90 (s, 3H), 3.78 (s, 3H), 3.63 (s, 3H).
m/z: 456 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.02 (d, J=4.8 Hz, 2H), 8.86 (d, J=6.0 Hz, 1H), 8.44 (d, J=6.0 Hz, 1H), 7.66 (t, J=4.8 Hz, 1H), 7.39 (s, 1H), 7.10 (t, J=7.6 Hz, 2H), 6.92 (s, 1H), 6.74-6.71 (m, 2H), 6.62 (s, 1H), 3.90 (s, 3H), 3.78 (s, 3H), 3.63 (s, 3H).
A mixture of enantiomers of 2-([2,2′-bipyrimidin]-4-yl)-3-benzyl-5,6-dimethoxyisoindolin-1-one (170 mg) was separated by SFC (supercritical fluid chromatography) on a CHIRALCEL® OD column using liquid CO2 and MeOH [0.1% aqueous NH3 as modifier](38:62) to give 2-([2,2′-bipyrimidin]-4-yl)-3-benzyl-5,6-dimethoxyisoindolin-1-one (single enantiomer I) as a white solid (faster eluting enantiomer, 72 mg, 42%, m/z: 440 [M+H]+ observed), and 2-([2,2′-bipyrimidin]-4-yl)-3-benzyl-5,6-dimethoxyisoindolin-1-one (single enantiomer II) as a white solid (slower eluting enantiomer, 72 mg, 42%, m/z: 440 [M+H]+ observed).
m/z: 440 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.08 (d, J=4.8 Hz, 2H), 8.92 (d, J=6.0 Hz, 1H), 8.44 (d, J=6.0 Hz, 1H), 7.70 (t, J=4.8 Hz, 1H), 7.18 (s, 1H), 7.13 (s, 1H), 7.08-7.07 (m, 3H), 6.74-6.72 (m, 2H), 5.79-5.77 (m, 1H), 3.87 (s, 3H), 3.81 (s, 3H), 3.79-3.74 (m, 1H), 3.68-3.64 (m, 1H).
m/z: 440 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.08 (d, J=4.8 Hz, 2H), 8.92 (d, J=6.0 Hz, 1H), 8.44 (d, J=6.0 Hz, 1H), 7.70 (t, J=4.8 Hz, 1H), 7.18 (s, 1H), 7.13 (s, 1H), 7.08-7.07 (m, 3H), 6.74-6.72 (m, 2H), 5.79-5.77 (m, 1H), 3.87 (s, 3H), 3.81 (s, 3H), 3.79-3.74 (m, 1H), 3.68-3.64 (m, 1H).
A mixture of enantiomers of 2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(3,3,3-trifluoropropyl)isoindolin-1-one (320 mg) was separated by SFC (supercritical fluid chromatography) on a Phenomenex Cellulose-2@ column using liquid CO2 and MeOH [0.1% aqueous NH3 as modifier] (55:45) to give 2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(3,3,3-trifluoropropyl)isoindolin-1-one (single enantiomer I) as a white solid (faster eluting enantiomer, 161 mg, 50%, m/z: 446 [M+H]+ observed), and 2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(3,3,3-trifluoropropyl)isoindolin-1-one (single enantiomer II) as a white solid (slower eluting enantiomer, 154 mg, 48%, m/z: 446 [M+H]+ observed).
m/z: 446 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ9.04 (d, J=4.8 Hz, 2H), 8.92 (d, J=6.0 Hz, 1H), 8.52 (d, J=6.0 Hz, 1H), 7.67 (t, J=4.8 Hz, 1H), 7.41 (s, 1H), 7.31 (s, 1H), 5.69 (s, 1H), 3.91 (s, 3H), 3.87 (s, 3H), 2.98-2.89 (m, 1H), 2.46-2.42 (m, 1H), 2.00-1.92 (m, 1H), 1.82-1.72 (m, 1H).
m/z: 446 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ9.04 (d, J=4.8 Hz, 2H), 8.92 (d, J=6.0 Hz, 1H), 8.52 (d, J=6.0 Hz, 1H), 7.67 (t, J=4.8 Hz, 1H), 7.41 (s, 1H), 7.31 (s, 1H), 5.69 (s, 1H), 3.91 (s, 3H), 3.87 (s, 3H), 2.98-2.89 (m, 1H), 2.46-2.42 (m, 1H), 2.00-1.92 (m, 1H), 1.82-1.72 (m, 1H).
A mixture of enantiomers of 2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(6-methylpyridin-3-yl)isoindolin-1-one (200 mg) was separated by SFC (supercritical fluid chromatography) on a CHIRALCEL® OD column using liquid CO2 and MeOH [0.1% aqueous NH3 as modifier](65:45) to give 2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(6-methylpyridin-3-yl)isoindolin-1-one (single enantiomer I) as a white solid (faster eluting enantiomer, 49 mg, 24%, m/z: 441 [M+H]+ observed), and 2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(6-methylpyridin-3-yl)isoindolin-1-one (single enantiomer II) as a white solid (slower eluting enantiomer, 32 mg, 16%, m/z: 441 [M+H]+ observed).
m/z: 441 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.04 (d, J=4.8 Hz, 2H), 8.85 (d, J=5.6 Hz, 1H), 8.66 (d, J=1.6 Hz, 1H), 8.43 (d, J=6.4 Hz, 1H), 7.67 (t, J=4.8 Hz, 1H), 7.47 (dd, J=8.0, 2.4 Hz, 1H), 7.40 (s, 1H), 7.06 (d, J=8.4 Hz, 1H), 6.94 (s, 1H), 6.65 (s, 1H), 3.90 (s, 3H), 3.77 (s, 3H), 2.33 (s, 3H).
m/z: 441 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.04 (d, J=4.8 Hz, 2H), 8.85 (d, J=5.6 Hz, 1H), 8.66 (d, J=1.6 Hz, 1H), 8.43 (d, J=6.4 Hz, 1H), 7.67 (t, J=4.8 Hz, 1H), 7.47 (dd, J=8.0, 2.4 Hz, 1H), 7.40 (s, 1H), 7.06 (d, J=8.4 Hz, 1H), 6.94 (s, 1H), 6.65 (s, 1H), 3.90 (s, 3H), 3.77 (s, 3H), 2.33 (s, 3H).
A mixture of enantiomers 2-([2,2′-bipyrimidin]-4-yl)-5-chloro-3-ethyl-7-fluoroisoindolin-1-one was separated by SFC (supercritical fluid chromatography) on a CHIRALCEL® OD-3 column using liquid CO2 and MeOH [0.1% aqueous NH3 as modifier] (50:50) to give 2-([2,2′-bipyrimidin]-4-yl)-5-chloro-3-ethyl-7-fluoroisoindolin-1-one (single enantiomer I) as a white solid (faster eluting enantiomer, 35 mg, m/z: 370 [M+H]+ observed), and 2-([2,2′-bipyrimidin]-4-yl)-5-chloro-3-ethyl-7-fluoroisoindolin-1-one (single enantiomer II) as a white solid (slower eluting enantiomer, 25 mg, m/z: 370 [M+H]+ observed).
m/z: 370 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.05 (d, J=4.9 Hz, 2H), 8.97 (d, J=5.8 Hz, 1H), 8.50 (d, J=5.8 Hz, 1H), 7.80-7.78 (m, 1H), 7.70-7.63 (m, 2H), 5.81-5.78 (m, 1H), 2.85-2.72 (m, 1H), 2.24-2.12 (m, 1H), 0.39 (t, J=7.4 Hz, 3H).
m/z: 370 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.05 (d, J=4.9 Hz, 2H), 8.97 (d, J=5.8 Hz, 1H), 8.50 (d, J=5.8 Hz, 1H), 7.80-7.78 (m, 1H), 7.70-7.63 (m, 2H), 5.81-5.78 (m, 1H), 2.85-2.72 (m, 1H), 2.24-2.12 (m, 1H), 0.39 (t, J=7.4 Hz, 3H).
A mixture of enantiomers 2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(pyridin-2-yl)isoindolin-1-one was separated by SFC (supercritical fluid chromatography) on a CHIRALCEL® OD-3 column using liquid CO2 and MeOH [0.1% aqueous NH3 as modifier](50:50) to give 2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(pyridin-2-yl)isoindolin-1-one (single enantiomer I) as a white solid (faster eluting enantiomer, 65 mg, m/z: 465 [M+K]+ observed), and 2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-(pyridin-2-yl)isoindolin-1-one (single enantiomer II) as a white solid (slower eluting enantiomer, 83 mg, m/z: 465 [M+K]+ observed).
m/z: 465 [M+K]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 8.94 (d, J=4.8 Hz, 2H), 8.84 (d, J=5.7 Hz, 1H), 8.54 (d, J=5.8 Hz, 1H), 8.30 (d, J=5.0 Hz, 1H), 7.78-7.67 (m, 2H), 7.60 (t, J=4.8 Hz, 1H), 7.37 (s, 1H), 7.18-7.12 (m, 1H), 6.95 (s, 1H), 6.65 (s, 1H), 3.88 (s, 3H), 3.76 (s, 3H).
m/z: 465 [M+K]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 8.94 (d, J=4.8 Hz, 2H), 8.84 (d, J=5.7 Hz, 1H), 8.54 (d, J=5.8 Hz, 1H), 8.30 (d, J=5.0 Hz, 1H), 7.78-7.67 (m, 2H), 7.60 (t, J=4.8 Hz, 1H), 7.37 (s, 1H), 7.18-7.12 (m, 1H), 6.95 (s, 1H), 6.65 (s, 1H), 3.88 (s, 3H), 3.76 (s, 3H).
m/z: 406 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 8.99 (d, J=4.8 Hz, 2H), 7.41 (t, J=4.8 Hz, 1H), 7.33 (s, 1H), 6.90 (s, 1H), 5.97 (t, J=4.0 Hz, 1H), 3.99 (s, 3H), 3.96 (s, 3H), 2.78 (s, 3H), 2.40 (s, 3H), 1.96-1.92 (m, 2H), 0.62 (t, J=7.2 Hz, 3H).
m/z: 396 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 9.10 (d, J=4.8 Hz, 2H), 8.73 (s, 1H), 7.51-7.47 (m, 2H), 7.18 (d, J=10.4 Hz, 1H), 5.95 (t, J=4.0 Hz, 1H), 4.13 (s, 3H), 3.97 (s, 3H), 1.95-1.87 (m, 2H), 0.56 (t, J=7.2 Hz, 3H).
m/z: 484 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 9.14 (b.s., 2H), 8.87 (b.s., 1H), 8.66 (b.s., 1H), 7.58 (b.s., 1H), 7.38 (b.s., 1H), 6.85-6.63 (m, 5H), 4.13-4.10 (m, 4H), 3.98 (s, 3H), 3.89 (s, 3H).
m/z: 446 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 8.98 (d, J=4.8 Hz, 2H), 8.84 (d, J=5.6 Hz, 1H), 8.43 (d, J=5.6 Hz, 1H), 7.41 (t, J=4.8 Hz, 1H), 7.38 (s, 1H), 7.08 (s, 1H), 6.98 (d, J=5.6 Hz, 1H), 6.67 (s, 1H), 6.60 (d, J=5.6 Hz, 1H), 3.98 (s, 3H), 3.89 (s, 3H), 2.42 (s, 3H).
m/z: 404 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 9.02 (d, J=4.8 Hz, 2H), 8.89 (d, J=6.0 Hz, 1H), 8.52 (d, J=6.0 Hz, 1H), 7.44 (t, J=4.8 Hz, 1H), 7.35 (s, 1H), 6.97 (s, 1H), 5.92 (d, J=6.8 Hz, 1H), 3.99 (s, 3H), 3.97 (s, 3H), 3.01-2.93 (m, 1H), 2.26-2.16 (m, 1H), 1.78-1.55 (m, 5H).
m/z: 434 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 9.20 (d, J=4.8 Hz, 2H), 9.03 (d, J=6.0 Hz, 1H), 8.76 (d, J=6.0 Hz, 1H), 7.64 (t, J=4.8 Hz, 1H), 7.45 (s, 1H), 7.05 (s, 1H), 6.04 (d, J=3.2 Hz, 1H), 4.12-4.06 (m, 7H), 3.89-3.85 (m, 1H), 3.46-3.39 (m, 1H), 3.30-3.12 (m, 1H), 2.85-2.80 (m, 1H), 2.01-1.91 (m, 2H), 1.28-1.25 (m, 1H), 0.99-0.91 (m, 1H).
A microwave vial with stir bar was charged with 5-bromo-2-pyriimidin-2-yl-pyriimidine (48 mg, 0.2 mmol), 3-ethyl-5,6-dimethoxy-isoindolin-1-one (33 mg, 0.15 mmol), copper (I) iodide (2 mg, 0.01 mmol), rac-(1S,2S)-cyclohexane-1,2-diamine (2.5 mg, 0.02 mmol), and cesium carbonate (165 mg, 0.5 mmol) in anhydrous dioxane and then degassed with nitrogen for 5 minutes. The vial was sealed and heated at 120° C. for 48 hours. The reaction mixture was cooled to room temperature, filtered and evaporated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (eluants 0 to 10% methanol in dichloromethane) to furnish 2-([2,2′-bipyrimidin]-4-yl)-3-ethyl-5,6-dimethoxyisoindolin-1-one as a grey solid (11 mg, 14.4% yield, m/z: 378 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 9.17 to 9.02 (m, 4H), 7.45 (s, 1H), 7.30 (s, 1H), 6.77 (b.s., 1H), 4.00-3.98 (m, 1H), 3.93 (s, 3H), 3.91 (s, 3H), 2.59-2.53 (m, 1H), 2.43-2.38 (m, 2H), 0.89 (b.s., 3H).
The following examples were prepared in a similar manner as 2-([2,2′-bipyrimidin]-4-yl)-3-ethyl-5,6-dimethoxyisoindolin-1-one by coupling 3-ethyl-5,6-dimethoxy-isoindolin-1-one and an appropriately substituted halo-heteroaryl-pyrimidine.
m/z: 377 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 8.91 (d, J=4.4 Hz, 2H), 8.54 (dd, J=8.0, 0.8 Hz, 1H), 8.22 (dd, J=8.0, 0.8 Hz, 1H), 7.94 (dd, J=8.0, 7.6 Hz, 1H), 7.36 (s, 1H), 7.32 (t, J=4.8 Hz, 1H), 6.92 (s, 1H), 5.88 (q, J=2.8 Hz, 1H), 3.99 (s, 3H), 3.97 (s, 3H), 2.56-2.49 (m, 1H), 2.07-2.00 (m, 1H), 0.47 (t, J=7.2 Hz, 3H).
A mixture of enantiomers (15 mg) was separated by SFC (supercritical fluid chromatography) on a CHIRALPAK® OJ column to give 3-ethyl-5,6-dimethoxy-2-(2-(pyrimidin-2-yl)pyridin-4-yl)isoindolin-1-one (single enantiomer I) as a white solid (faster eluting enantiomer, 1.5 mg, 10% yield, m/z: 377 [M+H]+ observed) and 3-ethyl-5,6-dimethoxy-2-(2-(pyrimidin-2-yl)pyridin-4-yl)isoindolin-1-one (single enantiomer II) as a white solid (slower eluting enantiomer, 4.2 mg, 28% yield, m/z: 377 [M+H]+ observed).
m/z: 377 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 8.92 (d, J=4.8 Hz, 2H), 8.83 (d, J=5.6 Hz, 1H), 8.66 (d, J=2.0 Hz, 1H), 7.94 (dd, J=5.6, 2.0 Hz, 1H), 7.37 (s, 1H), 7.33 (t, J=4.8 Hz, 1H), 6.92 (s, 1H), 5.42 (q, J=2.0 Hz, 1H), 4.00 (s, 3H), 3.98 (s, 3H), 2.29-2.22 (m, 1H), 2.10-2.03 (m, 1H), 0.49 (t, J=7.6 Hz, 3H).
m/z: 377 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 8.92 (d, J=4.8 Hz, 2H), 8.83 (d, J=5.6 Hz, 1H), 8.66 (d, J=2.0 Hz, 1H), 7.94 (dd, J=5.6, 2.0 Hz, 1H), 7.37 (s, 1H), 7.33 (t, J=4.8 Hz, 1H), 6.92 (s, 1H), 5.42 (q, J=2.0 Hz, 1H), 4.00 (s, 3H), 3.98 (s, 3H), 2.29-2.22 (m, 1H), 2.10-2.03 (m, 1H), 0.49 (t, J=7.6 Hz, 3H).
m/z: 378 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 9.90 (d, J=2.8 Hz, 1H), 9.41 (d, J=2.8 Hz, 1H), 8.94 (dd, J=4.8, 2.8 Hz, 2H), 7.37 (dd, J=4.8, 2.4 Hz, 2H), 6.91 (d, J=2.8 Hz, 1H), 5.86 (q, J=2.0 Hz, 1H), 3.99 (d, J=2.8 Hz, 3H), 3.96 (d, J=2.8 Hz, 3H), 2.61-2.48 (m, 1H), 2.10-2.01 (m, 1H), 0.51-0.47 (m, 3H).
m/z: 392 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 9.00 (d, J=4.8 Hz, 2H), 8.49 (s, 1H), 7.41 (t, J=4.8 Hz, 1H), 7.34 (s, 1H), 6.89 (s, 1H), 5.84 (q, J=2.4 Hz, 1H), 3.99 (s, 3H), 3.97 (s, 3H), 2.73 (s, 3H), 2.70-2.65 (m, 1H), 2.08-2.02 (m, 1H), 0.46 (t, J=7.2 Hz, 3H).
m/z: 378 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 9.61 (d, J=2.0 Hz, 1H), 9.17 (d, J=2.0 Hz, 1H), 8.97 (dd, J=4.8, 2.0 Hz, 2H), 7.41-7.38 (m, 1H), 7.35 (d, J=2.0 Hz, 1H), 6.92 (s, 1H), 5.64 (q, J=2.0 Hz, 1H), 4.01 (d, J=1.6 Hz, 3H), 3.97 (d, J=1.6 Hz, 3H), 2.60-2.53 (m, 1H), 2.11-2.06 (m, 1H), 0.54-0.51 (m, 3H).
5,6-Dimethoxy-3-propylisoindolin-1-one:
To a solution of methyl 2-[(E)-tert-butylsulfinyliminomethyl]-4,5-dimethoxy-benzoate (985 mg, 3.01 mmol) in anhydrous dichloromethane (30 mL) under nitrogen at −78° C. was added n-propyl magnesium bromide (2 molar solution in THF, 9 mL, 18 mmol) dropwise. The reaction mixture was warmed to room temperature over a period of 3 hours. The mixture was cooled to 0° C. and quenched with dropwise addition of saturated aqueous ammonium chloride solution (5 mL) and stirred for 10 min. Additional saturated aqueous ammonium chloride solution (40 mL) was added and the organic layer was separated. The aqueous layer was further extracted with dichloromethane (2×40 mL). The combined organic layer was dried over sodium sulfate (20 g) and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-100% EtOAc/hexanes) to furnish 5,6-dimethoxy-3-propylisoindolin-1-one as a white solid (392 mg, 55% yield, m/z: 236 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 7.29 (s, 1H), 7.25 (s, 1H), 6.86 (s, 1H), 6.35 (broad s, 1H), 4.54 (q, J=4.0 Hz, 1H), 3.95 (s, 3H), 3.93 (s, 3H), 1.96-1.86 (m, 1H), 1.61-1.37 (m, 3H), 0.97 (t, J=7.2 Hz, 3H).
A microwave vial with stir bar was charged with 4-chloro-2-pyrimidin-2-yl-pyrimidine (40 mg, 0.21 mmol), 5,6-dimethoxy-3-propylisoindolin-1-one (52 mg, 0.22 mmol), Xantphos (35 mg, 0.06 mmol), tris(dibenzylideneaceone)dipalladium (15 mg, 0.02 mmol) and cesium carbonate (175 mg, 0.54 mmol) in anhydrous 1,4-dioxane (10 mL). The reaction mixture was degassed with nitrogen for 5 minutes. The vial was sealed and heated at 120° C. for 48 hours. The reaction mixture was cooled to room temperature, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-10% MeOH/CH2Cl2) to furnish 2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-propylisoindolin-1-one as a white solid (25 mg, 31% yield, m/z: 392 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 9.01 (d, J=4.8 Hz, 2H), 8.89 (d, J=5.6 Hz, 1H), 8.61 (d, J=5.6 Hz, 1H), 7.43 (t, J=4.8 Hz, 1H), 7.34 (s, 1H), 6.92 (s, 1H), 5.85 (q, J=2.0 Hz, 1H), 4.00 (s, 3H), 3.97 (s, 3H), 2.59-2.50 (m, 1H), 2.07-1.98 (m, 1H), 1.07-0.83 (m, 2H), 0.74 (t, J=7.2 Hz, 3H).
To a solution of methyl 2-[(E)-tert-butylsulfinyliminomethyl]-4,5-dimethoxy-benzoate (985 mg, 3.01 mmol) in anhydrous dichloromethane (30 mL) under nitrogen at −78° C. was added isobutyl magnesium bromide (2 molar solution in THF, 9 mL, 18 mmol) dropwise. The reaction mixture was warmed to room temperature over a period of 3 h. The reaction mixture was cooled to 0° C., quenched with dropwise addition of saturated aqueous ammonium chloride solution (5 mL) and stirred for 10 min. Additional saturated aqueous ammonium chloride solution (40 mL) was added and the organic layer was separated. The aqueous layer was further extracted with dichloromethane (2×40 mL). The combined organic layer was dried over sodium sulfate (20 g) and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-100% EtOAc/hexanes) to furnish 3-isobutyl-5,6-dimethoxyisoindolin-1-one as a white solid (413 mg, 55% yield, m/z: 250 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 7.29 (s, 1H), 7.25 (s, 1H), 6.84 (s, 1H), 6.61 (broad s, 1H), 4.55 (dd, J=10.0, 4.0 Hz, 1H), 3.96 (s, 3H), 3.94 (s, 3H), 1.85-1.69 (m, 2H), 1.49-1.42 (m, 1H), 1.07 (d, J=6.8 Hz, 3H), 0.98 (d, J=6.8 Hz, 3H).
A microwave vial with stir bar was charged with 4-chloro-2-pyrimidin-2-yl-pyrimidine (40 mg, 0.21 mmol), 3-isobutyl-5,6-dimethoxyisoindolin-1-one (55 mg, 0.22 mmol), Xantphos (35 mg, 0.06 mmol), tris(dibenzylideneacetone)dipalladium (15 mg, 0.02 mmol), and cesium carbonate (175 mg, 0.54 mmol) in anhydrous 1,4-dioxane (10 mL). The reaction mixture was degassed with nitrogen for 5 minutes. The vial was sealed and heated at 120° C. for 48 hours. The mixture was cooled to room temperature, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-10% MeOH/CH2Cl2) to furnish 2-([2,2′-bipyrimidin]-4-yl)-3-isobutyl-5,6-dimethoxyisoindolin-1-one as a white solid (35 mg, 42% yield, m/z: 406 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 9.00 (d, J=4.8 Hz, 2H), 8.89 (d, J=5.6 Hz, 1H), 8.59 (d, J=5.6 Hz, 1H), 7.43 (t, J=4.8 Hz, 1H), 7.36 (s, 1H), 6.94 (s, 1H), 5.85 (q, J=2.4 Hz, 1H), 4.00 (s, 3H), 3.98 (s, 3H), 2.13-1.99 (m, 2H), 1.70-1.60 (m, 1H), 0.90 (d, J=6.8 Hz, 3H), 0.75 (d, J=6.8 Hz, 3H).
The mixture of enantiomers of 2-([2,2′-bipyrimidin]-4-yl)-3-isobutyl-5,6-dimethoxyisoindolin-1-one (35 mg) was separated by SFC (supercritical fluid chromatography) on a CHIRALPAK® OD column to give 3-ethyl-5,6-dimethoxy-2-(2-pyrimidin-2-ylpyrimidin-4-yl)isoindolin-1-one (single enantiomer I) as a white solid (faster eluting enantiomer, 11 mg, 13% yield, m/z: 406 [M+H]+ observed), and 3-ethyl-5,6-dimethoxy-2-(2-pyrimidin-2-ylpyrimidin-4-yl)isoindolin-1-one (single enantiomer II) as a white solid (slower eluting enantiomer, 11.5 mg, 13% yield, m/z: 406 [M+H]+ observed).
m/z: 406 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 9.00 (d, J=4.8 Hz, 2H), 8.89 (d, J=5.6 Hz, 1H), 8.59 (d, J=5.6 Hz, 1H), 7.43 (t, J=4.8 Hz, 1H), 7.36 (s, 1H), 6.94 (s, 1H), 5.85 (q, J=2.4 Hz, 1H), 4.00 (s, 3H), 3.98 (s, 3H), 2.13-1.99 (m, 2H), 1.70-1.60 (m, 1H), 0.90 (d, J=6.8 Hz, 3H), 0.75 (d, J=6.8 Hz, 3H).
m/z: 406 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 9.00 (d, J=4.8 Hz, 2H), 8.89 (d, J=5.6 Hz, 1H), 8.59 (d, J=5.6 Hz, 1H), 7.43 (t, J=4.8 Hz, 1H), 7.36 (s, 1H), 6.94 (s, 1H), 5.85 (q, J=2.4 Hz, 1H), 4.00 (s, 3H), 3.98 (s, 3H), 2.13-1.99 (m, 2H), 1.70-1.60 (m, 1H), 0.90 (d, J=6.8 Hz, 3H), 0.75 (d, J=6.8 Hz, 3H).
To a solution of methyl 2-[(E)-tert-butylsulfinyliminomethyl]-4,5-dimethoxy-benzoate (985 mg, 3.01 mmol) in anhydrous dichloromethane (30 mL) under nitrogen at −78° C. was added phenyl magnesium bromide (3 molar solution in ether, 6 mL, 18 mmol) dropwise. The solution was warmed to room temperature over a period of 3 hours. The reaction mixture was cooled to 0° C. and quenched with dropwise addition of saturated aqueous ammonium chloride solution (5 mL) and stirred for 10 min. Additional saturated aqueous ammonium chloride solution (40 mL) was added and the organic layer was separated. The aqueous layer was further extracted with dichloromethane (2×40 mL). The combined organic layer was dried over sodium sulfate (20 g) and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-100% EtOAc/hexanes) to give 5,6-dimethoxy-3-phenylisoindolin-1-one as a white solid (484 mg, 60% yield, m/z: 270 [M+H]+ observed). 1H NMR (400 MHz, CDCl3) δ 7.38-7.33 (m, 3H), 7.32-7.24 (m, 2H), 6.63 (s, 1H), 6.61 (broad s, 1H), 5.51 (broad s, 1H), 3.93 (s, 3H), 3.82 (s, 3H). 2-([2,2′-Bipyrimidin]-4-yl)-5,6-dimethoxy-3-phenylisoindolin-1-one: A microwave vial with stir bar was charged with 4-chloro-2-pyrimidin-2-yl-pyrimidine (40 mg, 0.21 mmol), 5,6-dimethoxy-3-phenyl-isoindolin-1-one (60 mg, 0.22 mmol), Xantphos (35 mg, 0.06 mmol), tris(dibenzylideneaceone)dipalladium (15 mg, 0.02 mmol), and cesium carbonate (175 mg, 0.54 mmol) in anhydrous 1,4-dioxane (10 mL). The reaction mixture was degassed with nitrogen for 5 minutes. The vial was sealed and heated at 120° C. for 48 hours. The mixture was cooled to room temperature, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-10% MeOH/CH2Cl2) to give 2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-phenylisoindolin-1-one as a white solid (34 mg, 38.5% yield, m/z: 426 [M+H]+ observed). 1H NMR (400 MHz, DMSO-d6): δ 9.02 (d, J=4.8 Hz, 2H), 8.85 (d, J=5.6 Hz, 1H), 8.45 (d, J=5.6 Hz, 1H), 7.65 (t, J=4.8 Hz, 1H), 7.39-7.36 (m, 3H), 7.23-7.16 (m, 3H), 6.89 (s, 1H), 6.64 (s, 1H), 3.90 (s, 3H), 3.76 (s, 3H).
A mixture of enantiomers of 2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-phenylisoindolin-1-one (600 mg) was separated by SFC (supercritical fluid chromatography) on a CHIRALCEL® OD column using liquid CO2 and MeOH [0.1% aqueous NH3 as modifier](40:60) to give 2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-phenylisoindolin-1-one (single enantiomer I) as a gray solid (faster eluting enantiomer, 105 mg, 17%, m/z: 426 [M+H]+ observed), and 2-([2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-phenylisoindolin-1-one (single enantiomer II) as a yellow solid (slower eluting enantiomer, 259 mg, 43%, m/z: 426 [M+H]+ observed).
m/z: 426 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.02 (d, J=4.8 Hz, 2H), 8.85 (d, J=5.6 Hz, 1H), 8.45 (d, J=5.6 Hz, 1H), 7.65 (t, J=4.8 Hz, 1H), 7.39-7.36 (m, 3H), 7.23-7.16 (m, 3H), 6.89 (s, 1H), 6.64 (s, 1H), 3.90 (s, 3H), 3.76 (s, 3H).
m/z: 426 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.02 (d, J=4.8 Hz, 2H), 8.85 (d, J=5.6 Hz, 1H), 8.45 (d, J=5.6 Hz, 1H), 7.65 (t, J=4.8 Hz, 1H), 7.39-7.36 (m, 3H), 7.23-7.16 (m, 3H), 6.89 (s, 1H), 6.64 (s, 1H), 3.90 (s, 3H), 3.76 (s, 3H).
To a solution of methyl 2-[(E)-tert-butylsulfinyliminomethyl]-4,5-dimethoxy-benzoate (985 mg, 3.01 mmol) in anhydrous dichloromethane (30 mL) under nitrogen at −78° C. was added a solution of tert-butyl magnesium bromide (2 molar solution in ether, 9 mL, 18 mmol) dropwise. The mixture was warmed to room temperature over a period of 3 h. The reaction mixture was cooled to 0° C. and quenched with dropwise addition of saturated aqueous ammonium chloride solution (5 mL) and stirred for 10 min. Additional saturated aqueous ammonium chloride solution (40 mL) was added and the organic layer was separated. The aqueous layer was further extracted with dichloromethane (2×40 mL). The combined organic layer was dried over sodium sulfate (20 g) and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-100% EtOAc/hexanes) to furnish 3-(tert-butyl)-5,6-dimethoxyisoindolin-1-one as a white solid (240 mg, 32% yield, m/z: 250 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 7.30 (s, 1H), 6.96 (s, 1H), 6.57 (broad s, 1H), 4.22 (s, 1H), 3.94 (s, 3H), 3.93 (s, 3H), 1.00 (m, 9H).
A microwave vial with stir bar was charged with 4-chloro-2-pyrimidin-2-yl-pyrimidine (40 mg, 0.21 mmol), 3-tert-butyl-5,6-dimethoxyisoindolin-1-one (55 mg, 0.22 mmol), Xantphos (35 mg, 0.06 mmol), tris(dibenzylideneacetone)dipalladium (15 mg, 0.02 mmol), and cesium carbonate (175 mg, 0.54 mmol) in anhydrous dioxane (10 mL) was degassed with nitrogen for 5 minutes. The vial was sealed and heated at 120° C. for 48 hours. The reaction mixture was cooled to room temperature, filtered and the concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-10% MeOH/CH2Cl2) to furnish 2-([2,2′-bipyrimidin]-4-yl)-3-(tert-butyl)-5,6-dimethoxyisoindolin-1-one as a white solid (8.5 mg, 10% yield, m/z: 406 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 9.01 (d, J=4.8 Hz, 2H), 8.93 (d, J=5.6 Hz, 1H), 8.32 (d, J=5.6 Hz, 1H), 7.43 (t, J=4.8 Hz, 1H), 7.33 (s, 1H), 7.01 (s, 1H), 6.08 (s, 1H), 3.98 (s, 3H), 3.96 (s, 3H), 0.90 (s, 9H).
A suspension of methyl 2-iodo-4,5-dimethoxy-benzoate (2.5 g, 7.8 mmol) and copper (I) cyanide (1.0 g, 11.6 mmol) in dry DMF was heated at 150° C. for 2 hours. The reaction mixture was cooled to room temperature and a solution of NaCN (1 g, 20 mmol) in water (50 mL) was added. The suspension was stirred for 1 hour. The solid was filtered, rinsed with water (2×50 mL), and the solid was dissolved in CH2Cl2 (50 mL) and washed with water (50 mL). The organic layer was dried over MgSO4, filtered and evaporated to give methyl 2-cyano-4,5-dimethoxy-benzoate as an off-white solid (1.7 g, quantitative yield, m/z: 222 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 7.58 (s, 1H), 7.18 (s, 1H), 3.99 (s, 6H), 3.96 (s, 3H).
To a cooled suspension of methyl 2-cyano-4,5-dimethoxy-benzoate (0.87 g, 3.9 mmol) in dry Et2O (40 mL) at 0° C. was added titanium (IV) isopropoxide, (1.3 mL, 4.3 mmol). The suspension was stirred for 15 minutes then ethylmagnesium bromide (3.0M in Et2O, 2.6 mL, 7.8 mmol) was added dropwise. The reaction mixture was stirred at 0-5° C. for 1 hour then was slowly warmed to room temperature and stirred for 2 hours. The reaction was cooled in an ice-water bath and was carefully quenched with the dropwise addition of hydrochloric acid (2M in water). The mixture was stirred for 30 minutes then diluted with CH2Cl2 (50 mL) and water (25 mL). The resulting suspension was filtered and the filter cake was rinsed with CH2Cl2 (2×25 mL). The organic layer was separated and the aqueous layer was extracted with CH2Cl2 (2×25 mL). The combined organic layer was dried over MgSO4, filtered and evaporated under reduced pressure. The residue was purified via normal phase SiO2 chromatography (0-10% MeOH/CH2Cl2) to give 5′,6′-dimethoxyspiro[cyclopropane-1,3′-isoindoline]-1′-one as an orange-brown solid (514 mg, 59% yield, m/z: 220 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 7.33 (s, 1H), 6.92 (s, 1H), 6.45 (s, 1H), 3.94 (s, 3H), 3.93 (s, 3H), 1.58-1.51 (m, 2H), 1.42-1.36 (m, 2H).
A microwave vial was charged with 5′,6′-dimethoxyspiro[cyclopropane-1,3′-isoindoline]-1′-one, (52 mg, 0.24 mmol), Xantphos Pd G3, (26 mg, 0.03 mmol), 4-chloro-2-pyrimidin-2-yl-pyrimidine, (55 mg, 0.29 mmol), cesium carbonate, (232 mg, 0.71 mmol), and dry 1,4-dioxane (1 mL). The mixture was purged with nitrogen, the vial was sealed and heated at 110° C. overnight. The mixture was cooled to room temperature, diluted with CH2Cl2, filtered through a plug of CELITE® and evaporated. The residue was purified via reverse phase HPLC. The desired fraction was poured into sat. aqueous NaHCO3 solution and extracted with CH2Cl2 (3×10 mL). The combined organic layer was dried over Na2SO4, filtered and evaporated. The residue was lyophilized from CH3CN—H2O (1:1, 2 mL) to give 2′-([2,2′-bipyrimidin]-4-yl)-5′,6′-dimethoxyspiro[cyclopropane-1,1′-isoindolin]-3′-one as an off-white lyophilate (9.91 mg, 10.8% yield, m/z: 376 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 9.00 (d, J=4.8 Hz, 2H), 8.88 (d, J=5.8 Hz, 1H), 8.64 (d, J=5.9 Hz, 1H), 7.42 (t, J=4.8 Hz, 1H), 7.39 (s, 1H), 6.48 (s, 1H), 3.99 (s, 3H), 3.98 (s, 3H), 3.18-3.10 (m, 2H), 1.39-1.31 (m, 2H).
The following example was prepared in a similar manner as 2′-([2,2′-bipyrimidin]-4-yl)-5′,6′-dimethoxyspiro[cyclopropane-1,1′-isoindolin]-3′-one from methyl 2-cyano-4-fluoro-5-methoxy-benzoate.
m/z: 364 [M+H]+. 1H NMR (400 MHz, CDCl3): δ 9.01 (s, 3H), 8.65 (s, 1H), 7.51 (d, J=7.7 Hz, 1H), 7.46 (s, 1H), 6.82 (d, J=10.0 Hz, 1H), 3.99 (s, 3H), 3.19-3.11 (m, 2H), 1.39-1.30 (m, 2H).
To a stirred mixture of 2-bromo-4,5-difluoro-benzaldehyde (8.0 g, 36.2 mmol) in MeOH (40 mL) was added sodium methoxide (2.35 g, 43.4 mmol). The mixture was stirred at room temperature overnight then warmed to 50° C. for 24 hours. The reaction mixture was cooled to room temperature and the solvent evaporated under reduced pressure. To the waxy yellow solid was added water (50 mL) and the suspension was stirred for 30 minutes. The resulting solid was filtered, rinsed with water (50 mL) and partially dried by suction. The solid was dissolved in EtOAc (50 mL), dried over Na2SO4, filtered and evaporated. The solid was purified via normal phase SiO2 chromatography (5% EtOAc/hexanes isocratic elution). The desired fractions were collected and evaporated to give 2-bromo-5-fluoro-4-methoxy-benzaldehyde as a white solid (3.40 g, 40% yield, m/z: 233 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 10.17 (d, J=3.2 Hz, 1H), 7.65 (d, J=11.0 Hz, 1H), 7.17 (d, J=7.2 Hz, 1H), 3.98 (s, 3H).
To a stirred solution of (S)-2-methylpropane-2-sulfinamide (2.50 g, 20.6 mmol) in dry THE (50 mL) was added titanium(IV) ethoxide (7.20 mL, 34.3 mmol). The mixture was stirred under nitrogen atmosphere for 10 minutes then 2-bromo-5-fluoro-4-methoxy-benzaldehyde (4.0 g, 17.2 mmol) was added as a solid. The pale-yellow suspension was heated at 70° C. under a nitrogen atmosphere for 72 hours. The mixture was cooled to 0-5° C. and quenched with the slow addition of water (100 mL) then EtOAc (200 mL) was added. The resulting suspension was filtered through a plug of CELITE®. The filtrate layers were separated. The organic layer was washed with water (50 mL), dried over MgSO4, filtered through plug of CELITE®. The filtrate was evaporated and subjected to high vacuum for 1 hour to give (S,E)-N-(2-bromo-5-fluoro-4-methoxybenzylidene)-2-methylpropane-2-sulfinamide as a viscous yellow resin, which was used in the next step without further purification (m/z: 336 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 8.82 (d, J=2.4 Hz, 1H), 7.79 (d, J=11.7 Hz, 1H), 7.17 (d, J=7.6 Hz, 1H), 3.95 (s, 3H), 1.26 (s, 9H).
The crude, yellow resin was dissolved in dry THF (100 mL) then cooled to −40° C. in a dry ice-acetonitrile bath for 1 hour followed by dropwise addition of ethylmagnesium bromide (3.0 M in Et2O, 7.5 mL, 22.5 mmol). The mixture was stirred at −40° C. for 3 hours. The reaction was quenched with dropwise addition of aqueous NH4Cl solution (20 mL) at −40° C. The mixture was slowly warmed to room temperature, diluted with water (50 mL), and extracted with EtOAc (200 mL). The aqueous was extracted with EtOAc (50 mL). The combined organic layer was dried over Na2SO4, filtered and evaporated. The residue was purified via normal phase SiO2 chromatography (3% MeOH/CH2Cl2, isocratic elution). The desired fractions were evaporated under reduced pressure and subjected to high vacuum overnight to give, as a mixture of diastereomers, (S)—N-[1-(2-bromo-5-fluoro-4-methoxy-phenyl)propyl]-2-methyl-propane-2-sulfinamide as an off-white foam (5.89 g, 93% yield, m/z: 366 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 7.12 (dd, J=8.0, 2.6 Hz, 1H), 7.08 (dd, J=12.2, 4.3 Hz, 1H), 4.80-4.62 (m, 1H), 3.89-3.86 (m, 3H), 3.47-3.32 (m, 1H), 2.04-1.70 (m, 2H), 1.23-1.18 (m, 9H), 0.94-0.83 (m, 3H).
To a cooled solution of n-butyllithium (1.6M in hexanes, 5.30 mL, 8.5 mmol) in dry THE (10 mL) at −78° C. was added dropwise a solution of a mixture of diastereomers of (S)—N-[1-(2-bromo-5-fluoro-4-methoxy-phenyl)propyl]-2-methyl-propane-2-sulfinamide (1.0 g, 2.7 mmol) in dry THE (8 mL). The reaction was stirred at −78° C. for 5 minutes. Then a solution of excess diethyl carbonate (662 uL, 5.46 mmol) in dry THE (2 mL) was added dropwise at −78° C. and stirred at −78° C. for 1 hour. The reaction was removed from cold bath and slowly warmed to room temperature and stirred for 2 hours. The reaction was quenched with NH4Cl solution (10 mL) and water (10 mL). The mixture was extracted with EtOAc (3×50 mL). The combined organic layer was dried over Na2SO4, filtered and evaporated. The residue was purified via normal phase SiO2 chromatography (100% EtOAc, isocratic elution). The desired fractions were evaporated to yield 3-ethyl-5-fluoro-6-methoxy-isoindolin-1-one as waxy tan solid (121 mg, 16% yield, m/z: 210 [M+H]+ observed), which was used in the next step without further purification. 1H NMR (400 MHz, CDCl3): δ 7.41 (d, J=7.7 Hz, 1H), 7.13 (d, J=10.1 Hz, 1H), 6.23 (s, 1H), 4.56-4.48 (m, 1H), 3.94 (s, 3H), 2.02-1.88 (m, 1H), 1.74-1.60 (m, 1H), 0.93 (t, J=7.4 Hz, 3H).
A microwave vial with stir bar was charged with crude 3-ethyl-5-fluoro-6-methoxy-isoindolin-1-one (121 mg, 0.58 mmol), 4-chloro-2-pyrimidin-2-yl-pyrimidine (167.5 mg, 0.87 mmol), Xantphos Pd G3, (55.0 mg, 0.06 mmol), cesium carbonate (567 mg, 1.74 mmol), and dry 1,4-dioxane (3 mL). The reaction mixture was degassed with nitrogen for 5 minutes. The vial was sealed and heated at 110° C. for 4 hours. The reaction mixture was cooled to room temperature, diluted with CH2Cl2 (10 mL), filtered through a plug of CELITE®, the plug was rinsed with CH2Cl2, and the filtrate was evaporated under reduced pressure. The residue was purified via reverse phase HPLC. The desired fractions were poured into saturated aqueous NaHCO3 solution and extracted with CH2Cl2 (4×50 mL). The combined organic layer was dried over Na2SO4, filtered and evaporated under reduced pressure to give 3-ethyl-5-fluoro-6-methoxy-2-(2-pyrimidin-2-ylpyrimidin-4-yl)isoindolin-1-one as a pale yellow solid (103 mg, 47% yield, m/z: 366 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 9.02 (d, J=4.9 Hz, 2H), 8.93 (d, J=5.7 Hz, 1H), 8.63 (d, J=5.8 Hz, 1H), 7.49 (d, J=7.6 Hz, 1H), 7.45 (t, J=4.9 Hz, 1H), 7.26-7.18 (m, 1H), 5.88 (dd, J=5.5, 2.6 Hz, 1H), 3.99 (s, 3H), 2.78-2.62 (m, 1H), 2.17-2.02 (m, 1H), 0.50 (t, J=7.4 Hz, 3H).
A mixture of enantiomers (103.4 mg) was separated by SFC (supercritical fluid chromatography) on a CHIRALPAK® IG column to give 3-ethyl-5-fluoro-6-methoxy-2-(2-pyrimidin-2-ylpyrimidin-4-yl)isoindolin-1-one (single enantiomer I) as a white solid (faster eluting enantiomer, 46.5 mg, 45% yield, m/z: 366 [M+H]+ observed), and 3-ethyl-5-fluoro-6-methoxy-2-(2-pyrimidin-2-ylpyrimidin-4-yl)isoindolin-1-one (single enantiomer II) as a white (slower eluting enantiomer, 23.6 mg, 23% yield, m/z: 366 [M+H]+ observed).
m/z: 366 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 9.02 (d, J=4.9 Hz, 2H), 8.93 (d, J=5.7 Hz, 1H), 8.63 (d, J=5.8 Hz, 1H), 7.49 (d, J=7.6 Hz, 1H), 7.45 (t, J=4.9 Hz, 1H), 7.26-7.18 (m, 1H), 5.88 (dd, J=5.5, 2.6 Hz, 1H), 3.99 (s, 3H), 2.78-2.62 (m, 1H), 2.17-2.02 (m, 1H), 0.50 (t, J=7.4 Hz, 3H).
m/z: 366 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 9.02 (d, J=4.9 Hz, 2H), 8.93 (d, J=5.7 Hz, 1H), 8.63 (d, J=5.8 Hz, 1H), 7.49 (d, J=7.6 Hz, 1H), 7.45 (t, J=4.9 Hz, 1H), 7.26-7.18 (m, 1H), 5.88 (dd, J=5.5, 2.6 Hz, 1H), 3.99 (s, 3H), 2.78-2.62 (m, 1H), 2.17-2.02 (m, 1H), 0.50 (t, J=7.4 Hz, 3H).
A microwave vial with stir bar was charged with a solution of 1-ethyl-5-fluoro-6-methoxy-2-(2-pyrimidin-2-ylpyrimidin-4-yl)isoindoline (10.2 mg, 0.03 mmol) [faster eluting enantiomer] in dry 1,4-dioxane (2 mL). The oxygen gas was bubbled into the solution for 5 minutes to saturate. The vial was sealed and heated at 110° C. for 16 hours. The mixture was cooled and was bubbled with oxygen gas for 5 minutes, the reaction vial was resealed and heated at 110° C. for 24 hours. The mixture was cooled to room temperature and evaporated under reduced pressure. The residue was purified via reverse phase HPLC. The desired fractions were poured into saturated aqueous NaHCO3 solution and extracted with CH2Cl2 (3×15 mL). The combined organic layer was dried over Na2SO4, filtered and evaporated. The residue was lyophilized from HPLC grade CH3CN—H2O (1:1, 1.5 mL) to give 2-([2,2′-bipyrimidin]-4-yl)-3-ethyl-6-fluoro-5-methoxyisoindolin-1-one as an off-white lyophilate (3.6 mg, 31% yield, m/z: 366 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 9.07-8.81 (m, 3H), 8.67-8.58 (m, 1H), 7.61 (d, J=9.5 Hz, 1H), 7.47-7.41 (m, 1H), 7.01 (d, J=7.1 Hz, 1H), 5.92-5.86 (m, 1H), 4.01 (s, 3H), 2.85-2.68 (m, 1H), 2.17-2.01 (m, 1H), 0.50 (t, J=7.4 Hz, 3H).
The following example was prepared in a similar manner as 2-([2,2′-bipyrimidin]-4-yl)-3-ethyl-6-fluoro-5-methoxyisoindolin-1-one from the corresponding indoline and oxygen.
m/z: 366 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 9.07-8.81 (m, 3H), 8.67-8.58 (m, 1H), 7.61 (d, J=9.5 Hz, 1H), 7.47-7.41 (m, 1H), 7.01 (d, J=7.1 Hz, 1H), 5.92-5.86 (m, 1H), 4.01 (s, 3H), 2.85-2.68 (m, 1H), 2.17-2.01 (m, 1H), 0.50 (t, J=7.4 Hz, 3H).
To a stirred solution of (S)-2-methylpropane-2-sulfinamide (5.00 g, 41.3 mmol) in dry CH2Cl2 (100 mL) was added p-toluenesulfonic acid monohydrate (392 mg, 2.1 mmol), pyridine (170 uL, 2.1 mmol), powdered anhydrous magnesium sulfate, (24.8 g, 206.3 mmol) followed by 3-methoxypropanal (5 g, 56.75 mmol). The white suspension was stirred at room temperature for 72 hours. The reaction mixture was filtered through a plug of CELITE® and the filtrate was evaporated. The recovered pale yellow oily solid was purified via normal phase SiO2 chromatography (2% MeOH in CH2Cl2, isocratic elution). The desired fractions were collected and evaporated to give (S,E)-N-(3-methoxypropylidene)-2-methylpropane-2-sulfinamide as a pale orange oil (6.00 g, 76% yield, m/z: 192 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 8.09 (t, J=4.6 Hz, 1H), 3.68 (t, J=6.3 Hz, 2H), 3.34 (s, 3H), 2.78 (td, J=6.3, 4.5 Hz, 2H), 1.20 (s, 9H).
A 250 ml round bottom flask with stir bar, reflux condenser and gas inlet adapter was charged with 2-bromo-4-fluoro-5-methoxy-benzoic acid (10.00 g, 40.2 mmol), DMAP (0.50 g, 4.0 mmol), and dry THE (100 mL), followed by di-tert-butyl dicarbonate (13.2 g, 60.2 mmol). The reaction was heated at 75° C. for 18 hours. Additional di-tert-butyl dicarbonate (5.0 g) was added and the reaction mixture was heated at 75° C. for 72 hours. The reaction mixture was cooled to room temperature. The resulting suspension was filtered through a plug of diatomaceous earth and the filter cake rinsed with cold THF. The filtrate was evaporated to an oily solid and the residue was purified via normal phase SiO2 chromatography (50% EtOAc/hexanes, isocratic) to give tert-butyl 2-bromo-4-fluoro-5-methoxy-benzoate as a pale yellow viscous oil (10.5 g, 85% yield, m/z: 249 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 7.36 (d, J=8.8 Hz, 1H), 7.33 (d, J=10.6 Hz, 1H), 3.90 (s, 3H), 1.61 (s, 9H).
To a dried flask with stir bar with rubber septa was added a solution of tert-butyl 2-bromo-4-fluoro-5-methoxy-benzoate (1.00 g, 3.28 mmol) in dry THE (9 mL) under nitrogen. The mixture was cooled to −78° C. in an acetone-dry ice bath. After 30 minutes, n-butyllithium (1.6M in hexanes, 2.25 mL, 3.60 mmol) was added dropwise and the mixture was stirred for 5 minutes. A solution of (S,E)-N-(3-methoxypropylidene)-2-methylpropane-2-sulfinamide (0.69 g, 3.6 mmol) in dry THE (1 mL) was added dropwise. The reaction mixture was stirred for 1 hour at −78° C. then slowly warmed to room temperature and stirred for 2 hours. The reaction was quenched via the addition of saturated aqueous NH4Cl (20 mL) then diluted with EtOAc (50 mL) and the layers were separated. The aqueous was extracted with EtOAc (3×20 mL). The combined organic layer was dried over Na2SO4, filtered and evaporated. The residue was purified via normal phase SiO2 chromatography (70% EtOAc/Hexanes, then 100% EtOAc, then 5% MeOH/CH2Cl2). The desired fractions were collected and evaporated to give 5-fluoro-6-methoxy-3-(2-methoxyethyl)isoindolin-1-one as dark yellow resin (331 mg, 42% yield, m/z: 240 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 7.42 (d, J=7.7 Hz, 1H), 7.13 (dd, J=10.1, 0.7 Hz, 1H), 6.78 (s, 1H), 4.57 (dd, J=10.0, 3.0 Hz, 1H), 3.94 (s, 3H), 3.71-3.57 (m, 2H), 3.39 (s, 3H), 2.18-2.07 (m, 1H), 1.82-1.68 (m, 1H).
A microwave vial with stir bar was charged with crude 5-fluoro-6-methoxy-3-(2-methoxyethyl)isoindolin-1-one, (50.00 mg, 0.24 mmol), 4-chloro-2-pyrimidin-2-yl-pyrimidine (69.1 mg, 0.36 mmol), Xantphos Pd G3, (22.7 mg, 0.02 mmol), cesium carbonate (233.6 mg, 0.72 mmol) and dry 1,4-dioxane (3 mL). The reaction mixture was degassed with nitrogen for 5 minutes. The vial was sealed and heated at 110° C. for 6 hours. The reaction mixture was cooled to room temperature, diluted with CH2Cl2 (10 mL), filtered through a plug of CELITE®, rinsed, and evaporated. The residue was purified by reverse phase HPLC.
The desired fractions were collected, poured into saturated aqueous NaHCO3 solution, and extracted with CH2Cl2 (3×15 mL). The combined organic layer was dried over Na2SO4, filtered and evaporated to a resin. The resin was lyophilized from HPLC grade CH3CN—H2O (1:1, 1.5 mL) to give 2-([2,2′-bipyrimidin]-4-yl)-5-fluoro-6-methoxy-3-(2-methoxyethyl)isoindolin-1-one as an off-white lyophilate (22 mg, 22% yield, m/z: 396 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 9.01 (d, J=4.8 Hz, 2H), 8.93 (d, J=5.8 Hz, 1H), 8.62 (d, J=5.8 Hz, 1H), 7.48 (d, J=7.7 Hz, 1H), 7.44 (t, J=4.8 Hz, 1H), 7.33 (d, J=10.0 Hz, 1H), 5.87 (dd, J=6.3, 3.0 Hz, 1H), 3.99 (s, 3H), 3.45-3.35 (m, 1H), 3.34-3.22 (m, 1H), 3.17 (s, 3H), 2.67-2.54 (m, 1H), 2.49-2.37 (m, 1H).
The following example was prepared in a similar manner as 2-([2,2′-bipyrimidin]-4-yl)-5-fluoro-6-methoxy-3-(2-methoxyethyl)isoindolin-1-one (single enantiomer I) from the corresponding (R)-2-methylpropane-2-sulfinamide and 3-methoxypropanal.
m/z: 396 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 9.01 (d, J=4.8 Hz, 2H), 8.93 (d, J=5.8 Hz, 1H), 8.62 (d, J=5.8 Hz, 1H), 7.48 (d, J=7.7 Hz, 1H), 7.44 (t, J=4.8 Hz, 1H), 7.33 (d, J=10.0 Hz, 1H), 5.87 (dd, J=6.3, 3.0 Hz, 1H), 3.99 (s, 3H), 3.45-3.35 (m, 1H), 3.34-3.22 (m, 1H), 3.17 (s, 3H), 2.67-2.54 (m, 1H), 2.49-2.37 (m, 1H).
To a solution of 4-fluoro-3-methoxybenzonitrile (10 g, 66.2 mmol) in AcOH/H2O (1:1, 100 mL) was added dropwise bromine (7.5 mL, 146 mmol) at room temperature and the reaction mixture was heated at 50° C. for 16 h. The mixture was cooled to rt and poured into ice-cold water (100 mL) and stirred for 30 min. The resulting white precipitate was filtered and dried under vacuum to give 2-bromo-4-fluoro-5-methoxybenzonitrile as an off-white solid (11.5 g, 76% yield). 1H NMR (400 MHz, CDCl3): δ 7.38 (d, 1H), 7.21 (d, 1H), 3.19 (s, 3H).
To a solution of 2-bromo-4-fluoro-5-methoxybenzonitrile (11 g, 48.2 mmol) in EtOH (240 mL) was added triethylamine (20 mL, 144 mmol) at room temperature in a steel bomb. The reaction mixture was then degassed with argon for 10-15 min. To the reaction mixture was added 1,3-bis(diphenylphosphino)propane (3.0 g, 7.3 mmol) and Pd(OAc)2 (1.1 g, 4.8 mmol) with continued degassing for 10 min. The reaction mixture was stirred under CO pressure (200 psi) at 100° C. for 16 h. The mixture was concentrated under reduced pressure, diluted with water (50 mL), and extracted with EtOAc (2×350 mL). The combined organic layer was washed with saturated aqueous brine solution (100 mL), dried over anhydrous sulfate, filtered and evaporated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-20% EtOAc/petroleum ether) to give ethyl 2-cyano-5-fluoro-4-methoxybenzoate (8.5 g, 79% yield, m/z: 224 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 7.85 (d, 1H), 7.31 (d, 1H), 4.47-4.42 (q, 2H), 3.99 (s, 3H), 1.45-1.42 (t, 3H).
To a solution of ethyl 2-cyano-5-fluoro-4-methoxybenzoate (8.5 g, 38 mmol) in EtOH (200 mL) was added palladium (10 wt. % loading on carbon, 4.0 g, 3.8 mmol) at room temperature and stirred under H2 pressure (200 psi) in a steel bomb for 16 h. The reaction mixture was degassed and back filled with nitrogen, filtered through CELITE® and washed with MeOH (100 mL). The filtrate was evaporated under reduced pressure to give crude 6-fluoro-5-methoxyisoindolin-1-one as a white solid, which was used in the next step without further purification (6.1 g, 88% yield, m/z: 182 [M+H]+ observed).
To a solution of crude 6-fluoro-5-methoxyisoindolin-1-one (6.0 g, 33.1 mmol) in THF (60 mL) was added triethylamine (14 mL, 99.4 mmol), di-tert-butyl dicarbonate (8.7 g, 40 mmol) and DMAP (0.4 g, 3.31 mmol) and the mixture was stirred at room temperature for 6 h. The reaction mixture was diluted with water (200 mL) and extracted with EtOAc (2×200 mL). The combined organic layer was washed with saturated aqueous brine solution (100 mL), dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure. The crude compound was purified by normal phase SiO2 chromatography (0-30% EtOAc/petroleum ether) to give tert-butyl 6-fluoro-5-methoxy-1-oxoisoindoline-2-carboxylate as a white solid (6.1 g, 65% yield, m/z: 226 [M-(tert-Butyl)+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 7.55 (d, 1H), 6.99 (d, 1H), 4.69 (s, 2H), 3.97 (s, 3H), 1.59 (s, 9H).
To a cooled solution of tert-butyl 6-fluoro-5-methoxy-1-oxoisoindoline-2-carboxylate (6.0 g, 21 mmol) in THE (60 mL) was added dropwise ethyl magnesium bromide (3.0 M solution in Et2O, 21.5 mL, 64.5 mmol) at 0° C. under an inert atmosphere for 10 min. The reaction mixture was slowly warmed to room temperature and stirred for 3 h. The reaction mixture was cooled to 0° C., quenched with saturated aqueous ammonium chloride solution (100 mL), and the resulting mixture was extracted with CH2Cl2 (2×200 mL). The combined organic layer was washed with saturated aqueous brine solution (100 mL), dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure. The residue was triturated with n-pentane (50 mL), filtered and dried under vacuum to give tert-butyl 1-ethyl-6-fluoro-1-hydroxy-5-methoxyisoindoline-2-carboxylate as a reddish gummy solid, which was used in the next step without further purification (4.2 g, 63% yield, m/z: 312 [M+H]+ observed). 1-Ethylidene-6-fluoro-5-methoxyisoindoline:
To a solution of crude tert-butyl 1-ethyl-6-fluoro-1-hydroxy-5-methoxyisoindoline-2-carboxylate (4.1 g, 13.1 mmol) in CH2Cl2 (50 mL) at −15° C. was added triethylsilane (17 mL, 105 mmol), followed by borontrifluoride-diethyl ether complex (3.2 mL, 26 mmol) under an inert atmosphere. The reaction mixture was slowly warmed to room temperature and stirred for 24 h. The reaction mixture was cooled to 0° C. and basified with saturated aqueous sodium bicarbonate solution. The resulting mixture was extracted with CH2Cl2 (2×200 mL). The combined organic layer was washed with saturated aqueous brine solution (100 mL), dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure to give crude 1-ethylidene-6-fluoro-5-methoxyisoindoline, which was used in the next step without further purification (2.2 g, 87% yield, m/z: 194 [M+H]+ observed).
To a solution of crude 1-ethylidene-6-fluoro-5-methoxyisoindoline (2.2 g, 11.3 mmol) in MeOH (100 mL) was added palladium (10 wt. % loading on carbon, 1.0 g, 0.9 mmol) at room temperature and stirred under H2 atmosphere (balloon) for 4 h. The reaction mixture was degassed with nitrogen, filtered through CELITEe® and washed with MeOH (100 mL).
The filtrate was evaporated under reduced pressure to give crude 1-ethyl-6-fluoro-5-methoxyisoindoline as an orange gummy solid, which was used in the next step without further purification (1.1 g, 50% yield, m/z: 196 [M+H]+ observed).
To a solution of 1-ethyl-6-fluoro-5-methoxyisoindoline (0.2 g, 0.865 mmol) in THE (10 mL) was added DIPEA (0.44 mL, 2.6 mmol) and 2,4-dichloro-5-fluoro-pyrimidine (0.17 g, 1.03 mmol) at room temperature and stirred for 3 h. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (2×200 mL). The combined organic layer was washed with sat. aqueous brine solution (100 mL), dried (Na2SO4) and evaporated to dryness under reduced pressure to provide crude product. The crude compound was purified by normal phase SiO2 chromatography (0-30% ethyl acetate in petroleum ether) to afford 2-(2-chloro-5-fluoropyrimidin-4-yl)-1-ethyl-6-fluoro-5-methoxyisoindoline as a red solid (0.1 g, 35% yield, m/z: 326 [M+H]+ observed). 1H NMR (400 MHz, DMSO-d6): δ 7.96-7.95 (m, 1H), 6.98-6.95 (m, 1H), 6.89-6.87 (m, 1H), 5.56 (br s, 1H), 4.95 (br s, 2H), 3.90 (s, 3H), 2.00-2.04 (m, 1H), 1.87-1.83 (m, 1H), 0.70-0.66 (m, 3H).
To the solution of 2-(2-chloro-5-fluoropyrimidin-4-yl)-1-ethyl-6-fluoro-5-methoxyisoindoline (0.4 g, 1.23 mmol) in DMF (10 mL) were added 2-(tributylstannyl)pyrimidine (0.68 g, 1.84 mmol), tetraethylammonium chloride (0.2 g, 1.23 mmol), K2CO3 (0.34 g, 2.46 mmol, 2) at room temperature and degassed with N2 gas for 10 min. To this solution PdCl2(PPh3)2 (0.086 g, 0.12 mmol) was added and degassed with N2 gas for 10 min. The reaction mixture was heated to 90° C. and stirred for 12 h. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (2×100 mL). The organic layer was washed with sat. aqueous brine solution (100 mL), dried over Na2SO4 and evaporated to dryness under reduced pressure. The crude was purified by reverse phase HPLC to afford 1-ethyl-6-fluoro-2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)-5-methoxyisoindoline as an off-white solid (0.1 g, 22%, m/z: 370 [M+H]+ observed). 1H NMR (400 MHz, DMSO-d6): δ 8.97-8.96 (m, 2H), 8.45-8.44 (m, 1H), 7.61-7.59 (m, 1H), 7.30-7.26 (m, 2H), 5.62 (m, 1H), 5.07-4.95 (m, 2H), 3.96 (s, 3H), 2.33-2.32 (m, 1H), 1.88-1.83 (m, 1H), 0.59-0.55 (m, 3H).
A mixture of enantiomers of 1-ethyl-6-fluoro-2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)-5-methoxyisoindoline (120 mg) was separated by SFC (supercritical fluid chromatography) on a DAICEL CHIRALCEL® OD column using liquid MeOH (40%; 0.1% aqueous NH3 as modifier) to give 1-ethyl-6-fluoro-2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)-5-methoxyisoindoline (single enantiomer I) as a yellow solid (faster eluting enantiomer, 38 mg, 36% yield, m/z: 370 [M+H]+ observed) and 1-ethyl-6-fluoro-2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)-5-methoxyisoindoline (single enantiomer II) as a yellow solid (slower eluting enantiomer, 45 mg, 35% yield, m/z: 370 [M+H]+ observed).
In a vial, 1-ethyl-6-fluoro-2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)-5-methoxyisoindoline (68 mg, 0.18 mmol) was dissolved in 1,4-dioxane (2 mL) and the solution was bubbled with oxygen gas for 2 minutes. The reaction was sealed and heated at 100° C. for 20 hours. The solvent was concentrated under reduced pressure. The crude material was purified by normal phase SiO2 chromatography (0-5% MeOH/dichloromethane) to give 3-ethyl-5-fluoro-2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)-6-methoxyisoindolin-1-one as a white solid (8.9 mg, 13% yield, m/z: 384 [M+H]+ observed). H NMR (400 MHz, CDCl3): δ 9.02 (d, J=4.8 Hz, 2H), 8.91 (d, J=2.0 Hz, 1H), 7.50 (d, J=7.6 Hz, 1H), 7.45 (t, J=4.8 Hz, 1H), 7.23-7.16 (m, 1H), 5.93 (t, J=4.2 Hz, 1H), 3.98 (s, 3H), 2.09-1.95 (m, 2H), 0.60 (t, J=7.4 Hz, 3H).
The following examples were prepared in a similar manner as 3-ethyl-5-fluoro-2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)-6-methoxyisoindolin-1-one by oxidation of the corresponding isoindoline.
m/z: 398 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 9.01 (d, J=4.9 Hz, 2H), 8.91 (s, 1H), 7.51-7.40 (m, 2H), 7.20 (d, J=9.9 Hz, 1H), 5.92 (dd, J=4.8, 3.6 Hz, 1H), 4.19 (qd, J=7.0, 1.4 Hz, 2H), 2.11-1.89 (m, 2H), 1.51 (t, J=7.0 Hz, 3H), 0.59 (t, J=7.4 Hz, 3H).
m/z: 412 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 9.01 (d, J=4.8 Hz, 2H), 8.90 (d, J=2.0 Hz, 1H), 7.51-7.41 (m, 2H), 7.20 (d, J=9.8 Hz, 1H), 5.92 (t, J=4.2 Hz, 1H), 4.66 (p, J=6.1 Hz, 1H), 2.01 (dqd, J=14.8, 7.4, 4.4 Hz, 2H), 1.43 (d, J=6.0 Hz, 6H), 0.60 (t, J=7.4 Hz, 3H).
m/z: 398 [M+H]+ observed. 1H NMR (400 MHz, CDCl3) δ 9.02 (d, J=4.9 Hz, 2H), 8.91 (d, J=2.0 Hz, 1H), 7.52-7.40 (m, 2H), 7.22 (dd, J=10.0, 0.8 Hz, 1H), 5.92 (t, J=4.6 Hz, 1H), 3.97 (s, 3H), 1.99-1.81 (m, 2H), 1.18-1.04 (m, 1H), 1.05-0.91 (m, 1H), 0.81-0.70 (m, 3H).
To a solution of 5-bromo-2,2′-bipyrimidine (577 mg, 2.45 mmol) in DMF-toluene (10 mL, 1:1), was added 1-ethyl-5,6-difluoroisoindoline hydrochloride (450 mg, 0.95 mmol) and Cs2CO3 (1.59 g, 4.91 mmol) at room temperature. The reaction mixture was degassed with argon for 5 minutes. To the obtained mixture was added of Pd2(dba)3 (227 mg, 0.24 mmol), SPhos (306 mg, 0.74 mmol) and irradiated in microwave (Anton parr) for 1 h at 110° C. The reaction mixture was diluted with EtOAc (200 mL) and filtered through a CELITE® plug. The filtrate was washed with ice-cold saturated aqueous brine solution (2×100 mL), dried over Na2SO4, and evaporated to dryness under reduced pressure. The crude residue was purified by reverse phase HPLC to afford 2-(2,2′-bipyrimidin-5-yl)-1-ethyl-5,6-difluoroisoindoline as an off-white solid (220 mg, 31% yield, m/z: 340 [M+H]+ observed). 1H NMR (400 MHz, DMSO-d6): δ 8.91 (d, 2H), 8.45 (s, 2H), 7.57-7.49 (m, 3H), 5.43 (s, 1H), 4.85-4.70 (q, 2H), 2.50-2.13 (m, 1H), 1.92-1.87 (m, 1H), 0.56-0.53 (t, 3H).
A mixture of enantiomers (220 mg) was separated by chiral HPLC on OD-H column using n-hexanes/EtOH (45/55) to give 2-([2,2′-bipyrimidin]-5-yl)-1-ethyl-5,6-difluoroisoindoline (single enantiomer I) as a white solid (faster eluting enantiomer, 68 mg, 31%, m/z: 340 [M+H]+ observed), and 2-([2,2′-bipyrimidin]-5-yl)-1-ethyl-5,6-difluoroisoindoline (single enantiomer II) as a white solid (slower eluting enantiomer, 65 mg, 30%, m/z: 340 [M+H]+ observed).
In a vial, 2-([2,2′-bipyrimidin]-5-yl)-1-ethyl-5,6-difluoroisoindoline (single enantiomer I, 21 mg, 0.06 mmol) was dissolved in 1,4-dioxane (2 mL) and the solution was bubbled with oxygen gas for 2 minutes. The reaction was sealed and heated at 100° C. for 20 hours. The solvent was concentrated under vacuum, and the crude material was purified by normal phase SiO2 chromatography (0-5% MeOH/CH2Cl2) to give 2-([2,2′-bipyrimidin]-5-yl)-3-ethyl-5,6-difluoroisoindolin-1-one as a white solid (7.4 mg, 33% yield, m/z: 354 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 9.38 (s, 2H), 9.04 (d, J=4.9 Hz, 2H), 7.76 (dd, J=8.4, 7.1 Hz, 1H), 7.45 (t, J=4.8 Hz, 1H), 7.36 (ddd, J=8.9, 6.4, 0.8 Hz, 1H), 5.44 (t, J=4.1 Hz, 1H), 2.29-1.98 (m, 2H), 0.55 (t, J=7.3 Hz, 3H).
A small microwave vial was charged with 4-chloro-2,2′-bipyrimidine (0.05 g, 0.26 mmol, 1 eq), 5,7-difluoroisoindolin-1-one (0.05 g, 0.29 mmol, 1.1 eq), palladium (II) acetate (0.01 g, 0.03 mmol, 0.1 eq), Xantphos (0.05 g, 0.08 mmol, 0.3 eq), cesium carbonate (0.12 g, 0.36 mmol, 1.4 eq), and 5 Å molecular sieves (pellets). The vial was capped, purged with nitrogen, then 1.5 mL of dry 1,4-dioxane was added. Then nitrogen was bubbled through the solvent for 5 min. The reaction was then heated thermally at 115° C. overnight. The reaction mixture was cooled to room temp, diluted with EtOAc (50 mL), then washed successively with water (2×30 mL), and saturated aqeuous brine solution (1×30 mL). The organic layer was dried over Na2SO4 and filtered through a CELITE® pad. The filtrate was evaporated under reduced pressure and purified by normal phase SiO2 chromatography (0-5% MeOH/CH2Cl2) to afford 2-([2,2′-bipyrimidin]-4-yl)-5,7-difluoroisoindolin-1-one as an off-white solid (0.035 g, 42% yield, m/z: 326 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 9.04 (d, 2H), 8.94 (d, 1H), 8.67 (d, 1H), 7.46 (t, 1H), 7.09 (d, 1H), 6.94 (t, 1H), 5.31 (s, 2H).
The following compounds were prepared in the same manner as 2-([2,2′-bipyrimidin]-4-yl)-5,7-difluoroisoindolin-1-one from an appropriate isoindolinone and 4-chloro-2,2′-bipyrimidine.
m/z: 326 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.03 (d, 2H), 8.94 (d, 1H), 8.54 (d, 1H), 8.02-7.87 (m, 2H), 7.68 (t 1H), 5.14 (s, 2H).
m/z: 351 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 9.03 (d, 2H), 8.89 (d, 1H), 8.70 (d, 1H), 7.45 (t, 1H), 7.37 (s, 1H), 7.00 (s, 1H), 5.22 (s, 2H), 4.00 (s, 3H), 3.98 (s, 3H).
m/z: 364 [M+H]+ observed. 1H NMR (400 MHz, CD3OD): δ 9.05 (d, J=4.9 Hz, 2H), 8.86 (d, J=5.9 Hz, 1H), 8.39 (d, J=5.8 Hz, 1H), 7.72-7.63 (m, 2H), 6.96 (s, 1H), 4.58 (t, J=6.4 Hz, 2H), 3.95 (s, 3H), 3.92 (s, 3H), 3.12 (t, J=6.4 Hz, 2H).
m/z: 340 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 9.03 (d, 2H), 8.93 (d, 1H), 8.38 (d, 1H), 7.75 (d, 1H), 7.45 (t, 1H), 7.06 (t, 1H), 4.64 (t, 2H), 3.12 (t, 2H).
A small microwave vial was charged with 4-chloro-2,2′-bipyrimidine (0.04 g, 0.21 mmol, 1 eq), 6,7-dimethoxy-1,4-dihydroisoquinolin-3(2H)-one (0.05 g, 0.23 mmol, 1.1 eq), palladium (II) acetate (0.005 g, 0.02 mmol, 0.1 eq), Xantphos (0.04 g, 0.06 mmol, 0.3 eq), cesium carbonate (0.07 g, 0.23 mmol, 1.1 eq), and 5 Å molecular sieves (pellets). The vial was capped, purged with nitrogen, then dry 1,4-dioxane (1.5 mL) was added. Then nitrogen gas was bubbled through the mixture for 5 min. The reaction was heated at 115° C. overnight.
The reaction was cooled to room temp, diluted with EtOAc (50 mL), then washed successively with water (2×30 mL), and saturated aqueous brine solution (30 mL). The organic layer was dried over Na2SO4 and filtered through a CELITE® pad. The filtrate was evaporated under reduced pressure and purified by normal phase SiO2 chromatography (0-5% MeOH/CH2Cl2) to afford 2-([2,2′-bipyrimidin]-4-yl)-6,7-dimethoxy-1,4-dihydroisoquinolin-3(2H)-one as an off-white solid (21 mg, 28% yield, m/z: 364 [M+H]+ observed). 1H NMR (400 MHz, CDCl3): δ 9.05 (d, 2H), 8.88 (d, 1H), 8.31 (d, 1H), 7.47 (t, 1H), 6.90 (s, 1H), 6.76 (s, 1H), 5.36 (s, 2H), 3.89 (s, 3H), 3.92 (s, 3H), 3.79 (s, 2H).
To a mixture of 3-ethyl-5,6-dimethoxy-isoindolin-1-one (0.55 g, 2.40 mmol) and 2,4-dichloro-5-fluoro-pyrimidine (1.20 g, 7.20 mmol) in 1,4-dioxane (10 mL) was added Xantphos (0.14 g, 0.24 mmol), cesium carbonate (1.77 g, 5.45 mmol) and tris(dibenzylideneacetone)dipalladium(0) (0.75 g, 0.82 mmol) under N2. Then the reaction mixture was stirred at 80° C. for 16 hr. The mixture, combined with another batch at 0.15 g scale, was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (33-50% ethyl acetate/petroleum ether) to give 2-(2-chloro-5-fluoro-pyrimidin-4-yl)-3-ethyl-5,6-dimethoxy-isoindolin-1-one as a white solid (0.45 g, 40% yield). 1H NMR (400 MHz, CD3OD): δ 8.71 (m, 1H), 7.35 (s, 1H), 7.22 (s, 1H), 5.68 (t, J=4.0 Hz, 1H), 3.98 (s, 3H), 3.92 (s, 3H), 2.15-2.07 (m, 2H), 0.54 (t, J=7.2 Hz, 3H).
To a mixture of 2-(2-chloro-5-fluoro-pyrimidin-4-yl)-3-ethyl-5,6-dimethoxy-isoindolin-1-one (400 mg, 1.14 mmol) and 2-(tributylstannyl)pyrimidine (0.72 mL, 2.27 mmol) in 1,4-dioxane (10 mL) was added copper(I) iodide (20 mg, 0.95 mmol), followed by Pd(dppf)Cl2 (80 mg, 0.11 mmol) under N2. The mixture was stirred at 110° C. for 16 hours. The mixture was cooled to rt then filtered through a Celite® plug and concentrated under reduced pressure.
The residue was purified by reverse phase HPLC to afford 3-ethyl-2-(5-fluoro-2-pyrimidin-2-yl-pyrimidin-4-yl)-5,6-dimethoxy-isoindolin-1-one as a white solid (300 mg, 67% yield, m/z: 396 [M+H]+).
A mixture of enantiomers of 3-ethyl-2-(5-fluoro-2-pyrimidin-2-yl-pyrimidin-4-yl)-5,6-dimethoxy-isoindolin-1-one (300 mg) was separated by SFC (supercritical fluid chromatography) on a CHIRALCEL® OD column using liquid CO2 and MeOH [0.1% aqueous NH3 as modifier] (67:33) to give 3-ethyl-2-(5-fluoro-2-pyrimidin-2-yl-pyrimidin-4-yl)-5,6-dimethoxy-isoindolin-1-one (single enantiomer I) as a white solid (faster eluting enantiomer, 92 mg, 31%, m/z: 396 [M+H]+ observed), and 3-ethyl-2-(5-fluoro-2-pyrimidin-2-yl-pyrimidin-4-yl)-5,6-dimethoxy-isoindolin-1-one (single enantiomer II) as a white solid (slower eluting enantiomer, 83 mg, 28%, m/z: 396 [M+H]+ observed).
m/z: 396 [M+H]+ observed. 1H NMR (400 MHz, DMSO): δ 9.13 (d, J=2.4 Hz, 1H), 9.03 (d, J 4.8 Hz, 2H), 7.68 (t, J=4.8 Hz, 1H), 7.32 (d, J=8.4 Hz, 2H), 5.72 (t, J=4.0 Hz, 1H), 3.91 (s, 3H), 3.87 (s, 3H), 2.14-1.95 (m, 2H), 0.44 (t, J=7.2 Hz, 3H).
m/z: 396 [M+H]+ observed. 1H NMR (400 MHz, DMSO): δ 9.13 (d, J=2.4 Hz, 1H), 9.03 (d, J 4.8 Hz, 2H), 7.68 (t, J=4.8 Hz, 1H), 7.32 (d, J=8.4 Hz, 2H), 5.72 (t, J=4.0 Hz, 1H), 3.91 (s, 3H), 3.87 (s, 3H), 2.14-1.95 (m, 2H), 0.44 (t, J=7.2 Hz, 3H).
The following examples were prepared in a similar manner as 3-ethyl-2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)-5,6-dimethoxyisoindolin-1-one from an appropriately substituted isoindolinone and an appropriately substituted 2-chloropyrimidine.
A mixture of enantiomers of 3-ethyl-2-(6-fluoro-[2,2′-bipyrimidin]-4-yl)-5,6-dimethoxyisoindolin-1-one (73 mg) was separated by SFC (supercritical fluid chromatography) on a Chiralpak® AD column using liquid CO2 and MeOH [0.1% aqueous NH3 as modifier] (45:55) to give 3-ethyl-2-(6-fluoro-[2,2′-bipyrimidin]-4-yl)-5,6-dimethoxyisoindolin-1-one (single enantiomer I) as a white solid (faster eluting enantiomer, 20 mg, 26%, m/z: 396 [M+H]+ observed), and 3-ethyl-2-(6-fluoro-[2,2′-bipyrimidin]-4-yl)-5,6-dimethoxyisoindolin-1-one (single enantiomer II) as a white solid (slower eluting enantiomer, 20 mg, 26%, m/z: 396 [M+H]+ observed).
m/z: 396 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.07 (d, J=4.8 Hz, 2H), 8.19 (s, 1H), 7.71 (t, J=4.8 Hz, 1H), 7.32 (d, J=6.0 Hz, 2H), 5.64 (d, J=2.4 Hz, 1H), 3.91 (s, 3H), 3.87 (s, 3H), 2.81-2.76 (m, 1H), 2.20-2.14 (m, 1H), 0.36 (t, J=7.2 Hz, 3H).
m/z: 396 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.07 (d, J=4.8 Hz, 2H), 8.19 (s, 1H), 7.71 (t, J=4.8 Hz, 1H), 7.32 (d, J=6.0 Hz, 2H), 5.64 (d, J=2.4 Hz, 1H), 3.91 (s, 3H), 3.87 (s, 3H), 2.81-2.76 (m, 1H), 2.20-2.14 (m, 1H), 0.36 (t, J=7.2 Hz, 3H).
A mixture of enantiomers of 2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-phenylisoindolin-1-one (110 mg) was separated by SFC (supercritical fluid chromatography) on a CHIRALCEL® OD column using liquid CO2 and MeOH [0.1% aqueous NH3 as modifier] (40:60) to give 2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-phenylisoindolin-1-one (single enantiomer I) as a white solid (faster eluting enantiomer, 48 mg, 44%, m/z: 444 [M+H]+ observed), and 2-(5-fluoro-[2,2′-bipyrimidin]-4-yl)-5,6-dimethoxy-3-phenylisoindolin-1-one (single enantiomer II) as a white solid (slower eluting enantiomer, 49 mg, 44%, m/z: 444 [M+H]+ observed).
m/z: 444 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.06-9.03 (m, 3H), 7.68 (t, J=4.8 Hz, 1H), 7.40 (s, 1H), 7.35-7.24 (m, 5H), 6.91 (s, 1H), 6.72 (s, 1H), 3.91 (s, 3H), 3.78 (s, 3H).
m/z: 444 [M+H]+ observed. 1H NMR (400 MHz, DMSO-d6): δ 9.06-9.03 (m, 3H), 7.68 (t, J=4.8 Hz, 1H), 7.40 (s, 1H), 7.35-7.24 (m, 5H), 6.91 (s, 1H), 6.72 (s, 1H), 3.91 (s, 3H), 3.78 (s, 3H).
A mixture of enantiomers of 3-ethyl-2-(5′-fluoro-[2,2′-bipyrimidin]-4-yl)-5,6-dimethoxyisoindolin-1-one (80 mg) was separated by SFC (supercritical fluid chromatography) on a Chiralpak® AD column using liquid CO2 and EtOH [0.1% aqueous NH3 as modifier] (50:50) to give 3-ethyl-2-(5′-fluoro-[2,2′-bipyrimidin]-4-yl)-5,6-dimethoxyisoindolin-1-one (single enantiomer I) as a white solid (faster eluting enantiomer, 38 mg, 47%, m/z: 418 [M+Na]+ observed), and 3-ethyl-2-(5′-fluoro-[2,2′-bipyrimidin]-4-yl)-5,6-dimethoxyisoindolin-1-one (single enantiomer II) as a white solid (slower eluting enantiomer, 23 mg, 28%, m/z: 418 [M+Na]+ observed).
m/z: 418 [M+Na]+ observed. 1H NMR (400 MHz, CDCl3): δ 8.88 (s, 3H), 8.68 (s, 1H), 7.37 (s, 1H), 6.93 (s, 1H), 5.83 (d, J=2.8 Hz, 1H), 4.02 (s, 3H), 3.99 (s, 3H), 2.79-2.72 (m, 1H), 2.13-2.08 (m, 1H), 0.51 (t, J=7.2 Hz, 3H).
m/z: 418 [M+Na]+ observed. 1H NMR (400 MHz, CDCl3): δ 8.88 (s, 3H), 8.68 (s, 1H), 7.37 (s, 1H), 6.93 (s, 1H), 5.83 (d, J=2.8 Hz, 1H), 4.02 (s, 3H), 3.99 (s, 3H), 2.79-2.72 (m, 1H), 2.13-2.08 (m, 1H), 0.51 (t, J=7.2 Hz, 3H).
m/z: 384 [M+H]+ observed. 1H NMR (400 MHz, CDCl3): δ 9.02 (d, J=4.8 Hz, 2H), 8.91 (d, J=2.0 Hz, 1H), 7.50 (d, J=7.6 Hz, 1H), 7.45 (t, J=4.8 Hz, 1H), 7.23-7.16 (m, 1H), 5.93 (t, J=4.2 Hz, 1H), 3.98 (s, 3H), 2.09-1.95 (m, 2H), 0.60 (t, J=7.4 Hz, 3H).
Inhibition of HBsAg was determined in HepG2.2.15 cells. Cells were maintained in culture medium containing 10% fetal calf serum, G414, Glutamine, penicillin/streptomycin. Cells were seeded in 96-well collagen-coated plate at a density of 30,000 cells/well. Serially diluted compounds were added to cells next day at the final DMSO concentration of 0.5%. Cells were incubated with compounds for 2-3 days, after which medium was removed. Fresh medium containing compounds was added to cells for additional 3-4 days. At day 6 after exposure of compounds, supernatant was collected, the HBsAg immunoassay (microplate-based chemiluminescence immunoassay kits, CLIA, Autobio Diagnosics Co., Zhengzhou, China, Catalog #CL0310-2) was used to determine the level of HBsAg according to manufactory instruction. Dose-response curves were generated and the EC50 value (effective concentrations that achieved 50% inhibitory effect) were determined using XLfit software. In addition, cells were seeded at a density of 5,000 cells/well for determination of cell viability in the presence and absence of compounds by using CellTiter-Glo reagent (Promega).
Table 1 shows EC50 values obtained by the HBsAg assay for selected compounds.
The following exemplary embodiments are provided, the numbering of which is not to be construed as designating levels of importance.
Embodiment 1 provides a compound of formula (I), or a salt, solvate, geometric isomer, stereoisomer, tautomer, and any mixtures thereof:
wherein:
R1 is selected from the group consisting of:
X1 is a bond (absent) or CR2a, R2b.
X2 is a bond (absent) or CR2CR2d.
each occurrence of X3 is independently selected from the group consisting of NR7a, O, and S;
each occurrence of X4 is independently selected from the group consisting of NR7b and CR5e;
each occurrence of Y1 is independently selected from the group consisting of N and CR6a;
each occurrence of Y2 is independently selected from the group consisting of N and CR5a;
each occurrence of R2a, R2b, R2c, R2d, R2e, and R2f is independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, halogen, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 hydroxyalkyl, —OR′, —(CH2)0-2C(═O)OR′, and —(CH2)0-2N(R′)(R′), wherein each occurrence of R′ is independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, and optionally substituted C3-C8 cycloalkyl;
each occurrence of R3a, R3b, R3c and R3d is independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, halogen, cyano, nitro, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 hydroxyalkyl, —OR′, —SR, —S(═O)R′, —S(O)2R′, and —N(R′)(R′), wherein each occurrence of R′ is independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, and optionally substituted C3-C8 cycloalkyl;
each occurrence of R6a, R6b, R6c, and R6d is independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, halogen, cyano, nitro, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 hydroxyalkyl, —OR′, —SR′, —S(═O)R′, —S(O)2R′, and —N(R′)(R′), wherein each occurrence of R′ is independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, and optionally substituted C3-C8 cycloalkyl;
each occurrence of R7a and R7b is independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, and optionally substituted C3-C8 cycloalkyl;
each occurrence of R8 is independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, and optionally substituted C3-C8 cycloalkyl; and
each occurrence of R9 is independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, —S(═O)2 (optionally substituted C1-C6 alkyl), and —S(═O)2 (optionally substituted C3-C8 cycloalkyl).
Embodiment 2 provides the compound of Embodiment 1, which is
Embodiment 3 provides the compound of Embodiment 1, which is
Embodiment 4 provides the compound of Embodiment 1, which is:
Embodiment 5 provides the compound of any of Embodiments 1-4, wherein R1 is selected from the group consisting of:
wherein Ph is optionally substituted,
Embodiment 6 provides the compound of any of Embodiments 1-5, wherein each occurrence of R2a, R2b, R2c, R2d, R2e, and R2f is independently selected from the group consisting of H, C1-C6 alkyl, pyridinyl, and thiophenyl, each of which optionally substituted.
Embodiment 7 provides the compound of any of Embodiments 1-6, wherein R2a and R2b, and/or R2c and R2d, and/or R2e and R2f independently combine with the carbon atom to which both of them are bound to form a substituent selected from the group consisting of 1,1-cyclopropanediyl, 1,1-cyclobutanediyl, 1,1-cyclopentanediyl, and 1,1-cyclohexanediyl.
Embodiment 8 provides the compound of any of Embodiments 1-7, wherein the
wherein each occurrence of Ra is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, or tert-butyl, and wherein each occurrence of Rb is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, or tert-butyl.
Embodiment 9 provides the compound of any of Embodiments 1-8, wherein R1 is:
Embodiment 10 provides the compound of any of Embodiments 1-9, wherein each occurrence of alkyl, alkenyl, cycloalkyl, carbocyclyl, or heterocyclyl is independently optionally substituted with at least one substituent selected from the group consisting of C1-C6 alkyl, halogen, —OR″, phenyl, and —N(R″)(R″), wherein each occurrence of R″ is independently H, C1-C6 alkyl, or C3-C8 cycloalkyl.
Embodiment 11 provides the compound of any of Embodiments 1-10, wherein each occurrence of aryl or heteroaryl is independently optionally substituted with at least one substituent selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, halogen, —CN, —OR″, —N(R″)(R″), —NO2, —S(═O)2N(R″)(R″), acyl, and C1-C6 alkoxycarbonyl, wherein each occurrence of R″ is independently H, C1-C6 alkyl or C3-C8 cycloalkyl.
Embodiment 12 provides the compound of any of Embodiments 1-11, wherein each occurrence of aryl or heteroaryl is independently optionally substituted with at least one substituent selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, halogen, —CN, —OR″, —N(R″)(R″), and C1-C6 alkoxycarbonyl, wherein each occurrence of R″ is independently H, C1-C6 alkyl or C3-C8 cycloalkyl.
Embodiment 13 provides the compound of any of Embodiments 1-12, which is selected from the group consisting of:
Embodiment 14 provides a compound of any of Embodiments 1-13, which is selected from the group consisting of:
Embodiment 15 provides a compound of any of Embodiments 1-13, which is selected from the group consisting of:
Embodiment 16 provides a pharmaceutical composition comprising at least one compound of any of Embodiments 1-15 and a pharmaceutically acceptable carrier.
Embodiment 17 provides the pharmaceutical composition of Embodiment 15, further comprising at least one additional agent useful for treating hepatitis virus infection.
Embodiment 18 provides the pharmaceutical composition of Embodiment 17, wherein the at least one additional agent comprises at least one selected from the group consisting of reverse transcriptase inhibitors, capsid inhibitors, cccDNA formation inhibitors, RNA destabilizers, oligomeric nucleotides targeted against the HBV genome, immunostimulators, and GalNAc-siRNA conjugates targeted against an HBV gene transcript.
Embodiment 19 provides the pharmaceutical composition of Embodiment 18, wherein the oligomeric nucleotide comprises one or more siRNAs.
Embodiment 20 provides a method of treating, ameliorating, and/or preventing hepatitis virus infection in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one compound of any of Embodiments 1-15 and/or at least one pharmaceutical composition of any of Embodiments 16-19.
Embodiment 21 provides a method of reducing or minimizing levels of at least one selected from the group consisting of hepatitis B virus surface antigen (HBsAg), hepatitis B e-antigen (HBeAg), hepatitis B core protein, and pregenomic (pg) RNA, in a hepatitis B virus (HBV)-infected subject, the method comprising administering to the subject a therapeutically effective amount of at least one compound of any of Embodiments 1-15 and/or at least one pharmaceutical composition of any of Embodiments 16-19.
Embodiment 22 provides the method of any of Embodiments 20-21, wherein the at least one compound is administered to the subject in a pharmaceutically acceptable composition.
Embodiment 23 provides the method of any of Embodiments 20-22, wherein the subject is further administered at least one additional agent useful for treating the hepatitis virus infection.
Embodiment 24 provides the method of Embodiment 23, wherein the at least one additional agent comprises at least one selected from the group consisting of reverse transcriptase inhibitors, capsid inhibitors, cccDNA formation inhibitors, RNA destabilizers, oligomeric nucleotides targeted against the HBV genome, immunostimulators, and GalNAc-siRNA conjugates targeted against an HBV gene transcript.
Embodiment 25 provides the method of Embodiment 24, wherein the oligomeric nucleotide comprises one or more siRNAs.
Embodiment 26 provides the method of any of Embodiments 22-25, wherein the subject is co-administered the at least one compound and the at least one additional agent.
Embodiment 27 provides the method of any of Embodiments 23-26, wherein the at least one compound and the at least one additional agent are coformulated.
Embodiment 28 provides the method of any of Embodiments 20-27, wherein the subject is infected with hepatitis B virus (HBV) or co-infected with HBV-hepatitis D virus (HDV).
Embodiment 29 provides the method of any of Embodiments 20-28, wherein the subject is a mammal.
Embodiment 30 provides the method of any of Embodiments 20-29, wherein the mammal is a human.
The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety.
While this disclosure has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this disclosure may be devised by others skilled in the art without departing from the true spirit and scope of the disclosure. The appended claims are intended to be construed to include all such embodiments and equivalent variations.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US20/60203 | 11/12/2020 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 62934893 | Nov 2019 | US |
